<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2804245223
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GAZYVA 25 mg/ml concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OBINUTUZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        14662.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ROCHE DIAGNOSTICS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ROCHE DIAGNOSTICS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ROCHE
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XC15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>What Gazyva is</strong></p><p dir="ltr"><strong>Gazyva contains the active substance obinutuzumab, which belongs to a group of medicines called &ldquo;monoclonal antibodies&rdquo;. Antibodies work by attaching themselves to specific targets in your body.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>What Gazyva is used for</strong></p><p dir="ltr"><strong>Gazyva can be used in adults to treat two different types of cancer</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Chronic lymphocytic leukaemia (also called &ldquo;CLL&rdquo;)</strong></p><p dir="ltr"><strong>∙ Gazyva is used in patients who have not had any treatment for CLL before and who have other illnesses which make it unlikely that they would be able to tolerate a full dose of a different medicine used to treat CLL called fludarabine.</strong></p><p dir="ltr"><strong>∙ Gazyva is used together with another medicine for cancer called chlorambucil.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Follicular lymphoma (also called &ldquo;FL&rdquo;)</strong></p><p dir="ltr"><strong>∙ &nbsp; Gazyva is used in patients who have not had any treatment for FL&nbsp;</strong></p><p dir="ltr"><strong>∙ &nbsp; Gazyva is used in patients who have had at least one treatment with a medicine called rituximab before and whose FL has come back or got worse during or after this treatment.&nbsp;</strong></p><p dir="ltr"><strong>∙ &nbsp; At the start of treatment for FL, Gazyva is used together with other medicines for cancer.&nbsp;</strong></p><p dir="ltr"><strong>∙ &nbsp; Gazyva can then be used on its own for up to 2 years as a &ldquo;maintenance treatment&rdquo;.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>How Gazyva works</strong></p><p dir="ltr"><strong>∙ CLL and FL are types of cancer that affect white blood cells called &ldquo;B-lymphocytes&rdquo;. The affected &ldquo;B-lymphocytes&rdquo; multiply too quickly and live too long. Gazyva binds to targets on the surface of the affected &ldquo;B-lymphocyte&rdquo; cells and causes them to die.&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>∙ When Gazyva is given to patients with CLL or FL together with other medicines for cancer - this slows down the time it takes for their disease to get worse.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>You must not be given Gazyva if:</strong></p><p dir="ltr"><strong>∙ you are allergic to obinutuzumab or any of the other ingredients of this medicine (listed in section&nbsp;6).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you are not sure talk to your doctor or nurse before being given Gazyva.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Warnings and precautions&nbsp;</strong></p><p dir="ltr"><strong>Talk to your doctor or nurse before you are given Gazyva if:</strong></p><p dir="ltr"><strong>∙ you have an infection, or have had an infection in the past which lasted a long time or keeps coming back&nbsp;</strong></p><p dir="ltr"><strong>∙ you have ever taken, or been given, medicines which affect your immune system (such as chemotherapy or immunosuppressants)</strong></p><p dir="ltr"><strong>∙ you are taking medicines for high blood pressure or medicines used to thin your blood &ndash; your doctor might need to alter how you take these</strong></p><p dir="ltr"><strong>∙ you have ever had heart problems</strong></p><p dir="ltr"><strong>∙ you have ever had brain problems (such as memory problems, difficulty moving or feeling sensations in your body, eyesight problems)</strong></p><p dir="ltr"><strong>∙ you have ever had breathing problems or lung problems</strong></p><p dir="ltr"><strong>∙ you have ever had&nbsp; &ldquo;hepatitis B&rdquo; - a type of liver disease&nbsp;</strong></p><p dir="ltr"><strong>∙ you are due to have a vaccine or you know you may need to have one in the near future.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If any of the above apply to you (or you are not sure), talk to your doctor or nurse before you are given Gazyva.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pay attention to the following side effects&nbsp;</strong></p><p dir="ltr"><strong>Gazyva can cause some serious side effects that you need to tell your doctor or nurse about straight away. These include:&nbsp;</strong></p><p dir="ltr"><strong>Infusion related reactions&nbsp;</strong></p><p dir="ltr"><strong>∙ Tell your doctor or nurse straight away if you get any of the infusion related reactions listed at the start of section 4. Infusion related reactions can happen during the infusion or up to 24&nbsp;hours after the infusion.&nbsp;</strong></p><p dir="ltr"><strong>∙ If you get an infusion related reaction, you may require additional treatment, or the infusion may need to be slowed down or stopped. When these symptoms go away, or improve, the infusion can be continued. These reactions are more likely to happen with the first infusion. Your doctor may decide to stop treatment with Gazyva if you have a severe infusion related reaction.</strong></p><p dir="ltr"><strong>∙ Before each infusion of Gazyva, you will be given medicines which help to reduce possible infusion related reactions or &ldquo;tumour lysis syndrome&rdquo;.&nbsp; Tumour lysis syndrome is a potentially life-threatening complication, caused by chemical changes in the blood due to the breakdown of dying cancer cells (see section 3).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Progressive multifocal leukoencephalopathy (also called &ldquo;PML&rdquo;)</strong></p><p dir="ltr"><strong>∙ PML is a very rare and life-threatening brain infection that has been reported in very few patients having treatment with Gazyva.&nbsp;</strong></p><p dir="ltr"><strong>∙ Tell your doctor or nurse straight away if you have memory loss, trouble speaking, difficulty walking or problems with your eyesight.&nbsp;</strong></p><p dir="ltr"><strong>∙ If you had any of these symptoms before treatment with Gazyva, tell your doctor straight away if you notice any changes in them. You may need medical treatment.</strong></p><p><br /><br />&nbsp;</p><p dir="ltr"><strong>Infections&nbsp;</strong></p><p dir="ltr"><strong>∙ Tell your doctor or nurse straight away if you get any signs of infection after your Gazyva treatment (see &quot;Infections&quot; in section 4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Children and adolescents</strong></p><p dir="ltr"><strong>Do not give Gazyva to children or young people under 18&nbsp;years of age. This is because there is no information about its use in these age groups.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Other medicines and Gazyva</strong></p><p dir="ltr"><strong>Tell your doctor or nurse if you are taking, have recently taken or might start taking any other medicines. This includes medicines obtained without a prescription and herbal medicines.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pregnancy&nbsp;</strong></p><p dir="ltr"><strong>∙ Tell your doctor or nurse if you are pregnant, think you might be pregnant or are planning to have a baby. They will help you weigh up the benefit of continuing Gazyva against the risk to your baby.&nbsp;</strong></p><p dir="ltr"><strong>∙ If you become pregnant during treatment with Gazyva, tell your doctor or nurse as soon as possible. This is because treatment with Gazyva may affect yours or the baby&rsquo;s health.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Breast-feeding</strong></p><p dir="ltr"><strong>∙ Do not breast-feed during treatment with Gazyva or for 18&nbsp;months after stopping treatment with Gazyva. This is because small amounts of the medicine may pass into your breast milk.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Contraception</strong></p><p dir="ltr"><strong>∙ Use an effective method of contraception while being treated with Gazyva.</strong></p><p dir="ltr"><strong>∙ Continue to use effective contraception for 18&nbsp;months after stopping treatment with Gazyva.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Driving and using machines&nbsp;</strong></p><p dir="ltr"><strong>Gazyva is not likely to affect your ability to drive, cycle or use any tools or machines. However, if you get an infusion related reaction, (see section 4), do not drive, cycle or use any tools or machines until the reaction stops.</strong></p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>How Gazyva is given</strong></p><p dir="ltr"><strong>Gazyva is given under the supervision of a doctor experienced in such treatment. It is given into a vein as a drip (intravenous infusion) over several hours.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The Gazyva treatment</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Chronic lymphocytic leukaemia</strong></p><p dir="ltr"><strong>∙ You will be given&nbsp;6 treatment cycles of Gazyva in combination with another medicine for cancer called chlorambucil. Each cycle lasts 28&nbsp;days.&nbsp;</strong></p><p dir="ltr"><strong>∙ On Day&nbsp;1 of your first cycle, you will be given part of your first Gazyva dose of 100 milligrams (mg) very slowly. Your doctor/nurse will monitor you carefully for infusion related reactions.&nbsp;</strong></p><p dir="ltr"><strong>∙ If you do not have an infusion related reaction following the small part of your first dose, you may be given the rest of your first dose (900&nbsp;mg) on the same day.&nbsp;</strong></p><p dir="ltr"><strong>∙ If you do have an infusion related reaction following the small part of your first dose, you will be given the rest of your first dose on Day&nbsp;2.</strong></p><p><br /><br /><br />&nbsp;</p><p dir="ltr"><strong>A typical schedule is shown below.&nbsp;</strong></p><p dir="ltr"><strong>Cycle 1 - this will include three doses of Gazyva in the 28 days:</strong></p><p dir="ltr"><strong>∙ Day&nbsp;1 &ndash; part of your first dose (100&nbsp;mg)</strong></p><p dir="ltr"><strong>∙ Day&nbsp;2 or Day 1 (continued) &ndash; remainder of first dose 900&nbsp;mg</strong></p><p dir="ltr"><strong>∙ Day&nbsp;8 &ndash; full dose (1,000&nbsp;mg)</strong></p><p dir="ltr"><strong>∙ Day&nbsp;15 &ndash; full dose (1,000&nbsp;mg)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Cycles 2, 3, 4, 5 and 6&nbsp; this will be just one dose of Gazyva in the 28 days:</strong></p><p dir="ltr"><strong>∙ Day&nbsp;1 &ndash; full dose (1,000&nbsp;mg).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Follicular lymphoma</strong></p><p dir="ltr"><strong>∙ You will be given&nbsp;6 or 8 treatment cycles of Gazyva in combination with other medicines for cancer - each cycle lasts 28 or 21 days depending on which other cancer medicines are given together with Gazyva.</strong></p><p dir="ltr"><strong>∙ This induction phase will be followed by a &ldquo;maintenance phase&rdquo; - during this time you will be given Gazyva every 2 months for up to 2 years as long as your disease does not progress. Based on your disease status after the initial treatment cycles your doctor will decide whether you will receive treatment in the maintenance phase.</strong></p><p dir="ltr"><strong>∙ A typical schedule is shown below.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Induction phase</strong></p><p dir="ltr"><strong>Cycle 1 - this will include three doses of Gazyva in the 28 or 21 days depending on which other cancer medicines are given together with Gazyva:</strong></p><p dir="ltr"><strong>∙ &nbsp; Day&nbsp;1 - full dose (1,000&nbsp;mg)</strong></p><p dir="ltr"><strong>∙ &nbsp; Day&nbsp;8 - full dose (1,000&nbsp;mg)</strong></p><p dir="ltr"><strong>∙ &nbsp; Day&nbsp;15 - full dose (1,000&nbsp;mg).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Cycles 2-6 or 2-8 - this will be just one dose of Gazyva in the 28 or 21 days depending on which other cancer medicines are given together with Gazyva:</strong></p><p dir="ltr"><strong>∙ &nbsp; Day&nbsp;1 - full dose (1,000&nbsp;mg).</strong></p><p dir="ltr"><strong>Maintenance phase</strong></p><p dir="ltr"><strong>∙ &nbsp; Full dose (1,000 mg) once every 2 months for up to 2 years as long as your disease does not progress.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Medicines given before each infusion&nbsp;</strong></p><p dir="ltr"><strong>Before each infusion of Gazyva, you will be given medicines to lessen the chance of getting infusion related reactions or tumour lysis syndrome. These may include:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ fluids&nbsp;</strong></p><p dir="ltr"><strong>∙ medicines to reduce a fever</strong></p><p dir="ltr"><strong>∙ medicines to reduce pain (analgesics)</strong></p><p dir="ltr"><strong>∙ medicines to reduce inflammation (corticosteroids) </strong></p><p dir="ltr"><strong>∙ medicines to reduce an allergic reaction (anti-histamines)</strong></p><p dir="ltr"><strong>∙ medicine to prevent tumour lysis syndrome (such as allopurinol).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you miss a Gazyva treatment</strong></p><p dir="ltr"><strong>If you miss your appointment, make another one as soon as possible. This is because for this medicine to be as effective as possible, it is important to follow the dosing schedule.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you have any further questions on the use of this medicine, ask your doctor or nurse.</strong></p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects have been reported with this medicine:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Serious side effects</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Infusion related reactions&nbsp;</strong></p><p dir="ltr"><strong>Tell your doctor or nurse straight away if you get any of the following symptoms during your infusion or up to 24&nbsp;hours after having your infusion:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Most frequently reported:</strong></p><p dir="ltr"><strong>∙ nausea</strong></p><p dir="ltr"><strong>∙ fatigue</strong></p><p dir="ltr"><strong>∙ dizziness</strong></p><p dir="ltr"><strong>∙ headache</strong></p><p dir="ltr"><strong>∙ diarrhoea</strong></p><p dir="ltr"><strong>∙ fever, flushing or chills</strong></p><p dir="ltr"><strong>∙ vomiting&nbsp;</strong></p><p dir="ltr"><strong>∙ shortness of breath</strong></p><p dir="ltr"><strong>∙ low or high blood pressure</strong></p><p dir="ltr"><strong>∙ heart beating very fast</strong></p><p dir="ltr"><strong>∙ chest discomfort</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Less frequently reported:&nbsp;</strong></p><p dir="ltr"><strong>∙ irregular heartbeat</strong></p><p dir="ltr"><strong>∙ swelling of the throat or airway&nbsp;</strong></p><p dir="ltr"><strong>∙ wheezing, difficulty breathing, tight chest or throat irritation</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you get any of the above, tell your doctor or nurse straight away.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Progressive multifocal leukoencephalopathy&nbsp;</strong></p><p dir="ltr"><strong>PML is a very rare and life-threatening brain infection that has been reported with Gazyva.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Tell your doctor or nurse straight away if you have</strong></p><p dir="ltr"><strong>∙ memory loss</strong></p><p dir="ltr"><strong>∙ trouble speaking&nbsp;</strong></p><p dir="ltr"><strong>∙ difficulty walking</strong></p><p dir="ltr"><strong>∙ problems with your eyesight</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you had any of these symptoms before treatment with Gazyva, tell your doctor straight away if you notice any changes in them. You may need medical treatment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Infections</strong></p><p dir="ltr"><strong>You may be more likely to get an infection during and after treatment with Gazyva. Often these are colds, but there have been cases of more severe infections. A type of liver disease called &ldquo;hepatitis B&rdquo; has also been reported to reoccur in patients who have had hepatitis B in the past.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Tell your doctor or nurse straight away if you get any signs of infection during and after your Gazyva treatment. These include:</strong></p><p dir="ltr"><strong>∙ fever</strong></p><p dir="ltr"><strong>∙ cough</strong></p><p dir="ltr"><strong>∙ chest pain</strong></p><p dir="ltr"><strong>∙ fatigue</strong></p><p dir="ltr"><strong>∙ painful rash</strong></p><p dir="ltr"><strong>∙ sore throat</strong></p><p dir="ltr"><strong>∙ burning pain when passing urine</strong></p><p dir="ltr"><strong>∙ feeling weak or generally unwell</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you had recurring or chronic infections before the start of Gazyva treatment, tell your doctor about it.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Other side effects:</strong></p><p dir="ltr"><strong>Tell your doctor or nurse if you notice any of the following side effects:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Very common (may affect more than&nbsp;1&nbsp;in&nbsp;10 people)</strong></p><p dir="ltr"><strong>∙ fever&nbsp;</strong></p><p dir="ltr"><strong>∙ lung infection</strong></p><p dir="ltr"><strong>∙ headache</strong></p><p dir="ltr"><strong>∙ joint pain, back pain</strong></p><p dir="ltr"><strong>∙ feeling weak</strong></p><p dir="ltr"><strong>∙ diarrhoea, constipation</strong></p><p dir="ltr"><strong>∙ sleeplessness</strong></p><p dir="ltr"><strong>∙ hair loss, itchiness</strong></p><p dir="ltr"><strong>∙ urinary tract infection, nose and throat inflammation, shingles</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ changes in blood tests:</strong></p><p dir="ltr"><strong>∙ anaemia (low levels of red blood cells)</strong></p><p dir="ltr"><strong>∙ low levels of all types of white blood cell (combined)&nbsp;</strong></p><p dir="ltr"><strong>∙ low levels of neutrophils (a type of white blood cell)&nbsp;</strong></p><p dir="ltr"><strong>∙ low level of platelets (a type of blood cell that helps your blood to clot)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ infection of upper airways (infection of nose, pharynx, larynx and sinuses), cough</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Common (may affect up to&nbsp;1&nbsp;in&nbsp;10 people)</strong></p><p dir="ltr"><strong>∙ red eye</strong></p><p dir="ltr"><strong>∙ cold sores</strong></p><p dir="ltr"><strong>∙ depression, anxiety</strong></p><p dir="ltr"><strong>∙ night sweats</strong></p><p dir="ltr"><strong>∙ ∙ flu (influenza)</strong></p><p dir="ltr"><strong>∙ weight increase</strong></p><p dir="ltr"><strong>∙ lymph node pain</strong></p><p dir="ltr"><strong>∙ runny or blocked nose</strong></p><p dir="ltr"><strong>∙ eczema</strong></p><p dir="ltr"><strong>∙ nose or throat inflammation</strong></p><p dir="ltr"><strong>∙ pain in mouth or throat</strong></p><p dir="ltr"><strong>∙ muscle and bone pain in your chest</strong></p><p dir="ltr"><strong>∙ skin cancer (squamous cell carcinoma)</strong></p><p dir="ltr"><strong>∙ bone pain, pain in arms and legs</strong></p><p dir="ltr"><strong>∙ irregular heart beat (atrial fibrillation), heart attack</strong></p><p dir="ltr"><strong>∙ problems with urinating, urinary incontinence</strong></p><p dir="ltr"><strong>∙ problems with digestion (e.g. heartburn), inflammation of the intestine, haemorrhoids&nbsp;</strong></p><p dir="ltr"><strong>∙ changes shown in blood tests:</strong></p><p dir="ltr"><strong>∙ low levels of lymphocytes (a type of white blood cells)</strong></p><p dir="ltr"><strong>∙ increase in potassium, phosphate or uric acid - which can cause kidney problems (part of tumour lysis syndrome)</strong></p><p dir="ltr"><strong>∙ decrease in potassium&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p dir="ltr"><strong>● a hole in the stomach or intestines (gastrointestinal perforation, especially in cases where the cancer affects the gastrointestinal tubes)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Tell your doctor or nurse if you notice any of the side effects listed above.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Reporting of side effects&nbsp;</strong></p><p dir="ltr"><strong>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Gazyva will be stored by the healthcare professionals at the hospital or clinic. The storage details are as follows:</strong></p><p dir="ltr"><strong>∙ Keep this medicine out of the sight and reach of children.</strong></p><p dir="ltr"><strong>∙ Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.</strong></p><p dir="ltr"><strong>∙ Store in a refrigerator (2 &deg;C8 &deg;C). Do not freeze.&nbsp;</strong></p><p dir="ltr"><strong>∙ Keep the container in the outer carton in order to protect from light.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Medicines should not be disposed of via wastewater or household waste. Your healthcare professional will throw away any medicines that are no longer being used. These measures will help protect the environment.</strong></p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>What Gazyva contains&nbsp;</strong></p><p dir="ltr"><strong>∙ The active substance is obinutuzumab: 1,000&nbsp;mg/40&nbsp;mL per vial corresponding to a concentration before dilution of 25&nbsp;mg/mL.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ The other ingredients are L-histidine, L-histidine hydrochloride monohydrate, trehalose dihydrate, poloxamer 188 and water for injections.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Gazyva is a concentrate for solution for infusion and is a colourless to slightly brown liquid. Gazyva is available in a pack containing 1 glass vial. 




            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>F. Hoffmann-La Roche Ltd,</strong></p><p dir="ltr"><strong>Grenzacherstrasse 124,&nbsp;</strong></p><p dir="ltr"><strong>CH-4070 Basel,&nbsp;</strong></p><p dir="ltr"><strong>Switzerland.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in October 2017.

To reports any side effect(s):

Saudi Arabia:

The National Pharmacovigilance and Drug Safety Centre (NPC)
Fax: +966-11-205-7662
Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.
Toll free phone: 8002490000
E-mail: npc.drug@sfda.gov.sa
Website: www.sfda.gov.sa/npc

 Other GCC States:
Please contact the relevant competent authority.
 


Council of Arab Health Ministers

This is a Medicament
Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.
Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.
The doctor and the pharmacist are the experts in medicines, their benefits and risks.
Do not by yourself interrupt the period of treatment prescribed for you.
Do not repeat the same prescription without consulting your doctor.
Keep all medicaments out of reach of children.

Council of Arab Health Ministers
Union of Arab Pharmacists


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="rtl"><strong>ما هو غازيفا:</strong></p><p dir="rtl"><strong>يحتوي غازيفا على المادة الفعالة أوبينوتوزوماب، وهو ينتمي إلى فصيلة من الأدوية تسمى &quot;الأجسام المضادة وحيدة النسيلة&quot;.&nbsp; وتعمل هذه الأجسام المضادة عن طريق الالتحام بأهداف معينة في الجسم.</strong></p><p><br /><br />&nbsp;</p><p dir="rtl"><strong>ما هو الغرض من استخدامه:</strong></p><p dir="rtl"><strong>يستخدم غازيفا لعلاج المرضى البالغين الذين يعانون من نوعين من السرطان:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>سرطان الدم الليمفاوي (ابيضاض الدم) المزمن:</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يستخدم غازيفا لعلاج المرضى الذين لم يسبق لهم الحصول على أي علاج لسرطان الدم الليمفاوي المزمن والذين يعانون من مرض آخر يحول دون مقدرتهم على تحمل جرعة كاملة من فلودارابين&nbsp; وهو علاج آخر يستخدم مع سرطان الدم الليمفاوي المزمن.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يستخدم غازيفا مع دوار آخر لعلاج السرطان يسمى كلورامبوسيل.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>سرطان الغدد الليمفاوية الجريبي:</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يستخدم غازيفا لعلاج المرضى الذين لم يسبق لهم الحصول على أي علاج لسرطان الغدد الليمفاوية الجريبي.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يستخدم غازيفا لعلاج المرضى الذين سبق لهم الحصول على علاج واحد على الأقل بدواء يسمى ريتوكسيماب والذين عاود سرطان الغدد الليمفاوية الجريبي الظهور لديهم مرة أخرى أو تفاقم لديهم هذا المرض أثناء هذا العلاج أو بعده.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>عندما يكون سرطان الغدد الليمفاوية الجريبي في بدايته، يستخدم غازيفا مقترنا بالأدوية الأخرى لعلاج السرطان.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يمكن استخدام غازيفا بمفرده لمدة عامين فيما يسمى بعلاج المداومة.</strong></p></li></ul><p dir="rtl"><strong>كيف يعمل غازيفا:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>سرطان الدم الليمفاوي (ابيضاض الدم) المزمن وسرطان الغدد الليمفاوية الجريبي هما نوعان من السرطان الذي يؤثر في خلايا الدم البيضاء التي تسمى &quot;الخلايا الليمفاوية ب&quot;.&nbsp; وهذه الخلايا تتضاعف بسرعة شديدة وتعيش فترة طويلة جدا.&nbsp; ويلتحم غازيفا مع الأهداف على سطح هذه الخلايا المتضررة مما يؤدي إلى موت هذه الخلايا.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>عند إعطاء غازيفا لمرضى سرطان الدم الليمفاوي المزمن وسرطان الغدد الليمفاوية الجريبي مع الأدوية الأخرى لعلاج السرطان، فإن ذلك يؤدي إلى تأخير تفاقم المرض.</strong></p></li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>يجب عليك عدم تناول دواء غازيفا في الحالات التالية:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>في حالة أن تعاني من حساسية للمادة الفعالة أوبينوتوزوماب أو أي من المكونات الأخرى لهذا الدواء (المذكورة في الجزء السادس).&nbsp;&nbsp;</strong></p></li></ul><p dir="rtl"><strong>استشر الطبيب أو التمريض قبل تناولك غازيفا في حالة عدم تأكدك.</strong></p><p dir="rtl"><strong>التحذيرات والاحتياطات:</strong></p><p dir="rtl"><strong>استشر الطبيب قبل تناول غازيفا في الحالات التالية:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>في حالة حدوث أي عدوى حالية أو سابقة استمرت لفترة من الوقت أو تعاود الظهور مرة أخرى.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>في حالة تناولك حاليا أو سابقا أي أدوية تؤثر في الجهاز المناعي (مثل العلاج الكيماوي أو مثبطات المناعة).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>في حالة تناولك أدوية لعلاج ضغط الدم المرتفع أو الأدوية التي تستخدم لترقيق الدم، فقد يحتاج الطبيب في هذه الحالة إلى تغيير طريقة تناولك لهذه الأدوية.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>في حالة حدوث مشكلات سابقة في القلب.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>في حالة حدوث مشكلات سابقة في المخ (مثل مشكلات الذاكرة، صعوبة الحركة أو وجود إحساسات في الجسم، مشكلات الإبصار).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>في حالة وجود مشكلات سابقة في التنفس أو الرئتين.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>في حالة أن يكون قد سبق لك الإصابة بالفيروس الكبدي ب.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كانت هناك أي تطعيمات مجدولة لك ويلزمك أخذها أن يكون هناك احتمالية لأن تحتاج الحصول على تطعيم في وقت قريب.</strong></p></li></ul><p dir="rtl"><strong>في حالة أن ينطبق عليك أي مما سبق (أو في حالة عدم تأكدك)، يجب عليك استشارة الطبيب أو التمريض قبل تناول غازيفا.</strong></p><p dir="rtl"><strong>انتبه إلى الآثار الجانبية التالية:</strong></p><p dir="rtl"><strong>من الممكن أن يسبب غازيفا بعض الآثار الجانبية الخطيرة التي تحتاج إلى أن تبلغ بها الطبيب أو التمريض على الفور.&nbsp; وتشمل هذه الآثار الجانبية ما يلي:</strong></p><p dir="rtl"><strong>الحساسية المفرطة المتعلقة بحقن المحلول:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>يجب عليك إبلاغ الطبيب أو التمريض على الفور في حالة حدوث أي من الآثار الجانبية المتعلقة بالمحلول المذكورة في بداية الجزء الرابع من هذه النشرة.&nbsp; وقد تحدث هذه التفاعلات والحساسية المتعلقة بالمحلول أثناء الحقن أو بعد الحقن بفترة زمنية تصل إلى 24 ساعة.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>قد تحتاج إلى الحصول على علاج إضافي أو إبطاء المحلول أو إيقافه، وذلك في حالة حدوث أي من أعراض الحساسية المفرطة تجاه بالمحلول.&nbsp; وعندما تتلاشى هذه الأعراض أو تتحسن، يمكن استمرار حقن المحلول.&nbsp; وتميل هذه الحساسية أكثر إلى الظهور مع أول محلول.&nbsp; وقد يقرر الطبيب إيقاف العلاج باستخدام غازيفا في حالة حدوثها بشكل حاد.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>قبل كل محلول من غازيفا، سوف يتم إعطاؤك أدوية أخرى تساعد على تخفيف احتمالية الإصابة بأعراض الحساسية المحتملة المتعلقة بالمحلول أو &quot;متلازمة تحلل الورم&quot;.&nbsp; وهي إحدى المضاعفات الخطيرة التي قد تسبب الوفاة، وتحدث نتيجة للتغيرات الكيميائية في الدم بسبب تكسير الخلايا السرطانية الميتة (انظر الجزء الثالث).</strong></p></li></ul><p dir="rtl"><strong>اعتلال بيضاء الدماغ متعدد البؤر التقدمي:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>اعتلال بيضاء الدماغ متعدد البؤر التقدمي هو عبارة عن عدوى خطيرة نادرة جدا في المخ مسببة للوفاة تم تسجيلها لدى عدد قليل جدا من المرضى الذين يعالجون باستخدام غازيفا.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يجب عليك إبلاغ الطبيب أو التمريض على الفور في حالة حدوث فقدان في الذاكرة أو مشكلات كلامية أو صعوبة في المشي أو مشكلات في الإبصار.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>في حالة وجود أي من هذه الأعراض قبل العلاج باستخدام غازيفا، يجب عليك إبلاغ الطبيب على الفور إذا لوحظ أي تغيرات في هذه الأعراض.&nbsp; فقد تحتاج إلى الخضوع للعلاج الطبي.</strong></p></li></ul><p dir="rtl"><strong>العدوى:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>يجب عليك إبلاغ الطبيب أو التمريض على الفور في حالة وجود أي علامات للعدوى بعد تناول غازيفا (انظر &quot;العدوى&quot; في الجزء الرابع).</strong></p></li></ul><p dir="rtl"><strong>الأطفال والمراهقون:</strong></p><p dir="rtl"><strong>لا يوصى باستخدام غازيفا مع الأطفال أو المراهقين.&nbsp; فآثار غازيفا على الأشخاص الذين تقل أعمارهم عن 18 عام غير معروفة.</strong></p><p dir="rtl"><strong>الأدوية الأخرى وغازيفا:</strong></p><p dir="rtl"><strong>أخبر الطبيب في حالة تناولك أو تناولت مؤخرا أو ربما تتناول أي أدوية أخرى، ويشمل ذلك الأدوية التي يتم الحصول عليها دون روشتة طبية من الصيدلية وأدوية العلاج بالأعشاب.</strong></p><p dir="rtl"><strong>الحمل:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>يجب إبلاغ الطبيب في حالة الحمل أو الشك في حدوث الحمل أو التخطيط للحمل.&nbsp; وهذا سوف يساعدك في الموازنة بين مزايا الاستمرار على غازيفا والأضرار المتعلقة بالجنين.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يجب إبلاغ الطبيب أو التمريض في أسرع وقت ممكن في حالة حدوث الحمل أثناء تناول غازيفا.&nbsp; وهذا لأن العلاج باستخدام غازيفا قد يضر بصحة الجنين.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>الرضاعة الطبيعية:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>يجب التوقف عن الرضاعة الطبيعية أثناء تناول غازيفا ولمدة 18 شهر بعد إيقاف العلاج.&nbsp; وهذا بسبب إمكانية انتقال كميات صغيرة من الدواء عبر حليب الثدي.</strong></p></li></ul><p dir="rtl"><strong>وسيلة منع الحمل:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>يجب استخدام وسيلة فعالة لمنع الحمل أثناء العلاج باستخدام غازيفا.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يجب الاستمرار على استخدام وسيلة منع حمل فعالة لمدة 18 شهر بعد إيقاف العلاج باستخدام غازيفا.</strong></p></li></ul><p dir="rtl"><strong>قيادة السيارات واستخدام الآلات:</strong></p><p dir="rtl"><strong>من غير المحتمل أن يؤثر غازيفا على قدرتك على قيادة السيارات أو الدراجات أو استخدام أي من الآلات أو الأدوات.&nbsp; ولكن يجب عليك التوقف عن القيادة واستخدام الآلات في حالة وجود أي من الآثار أو الحساسية المفرطة المتعلقة بالمحلول لحين تلاشي هذه الأعراض</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>يتم إعطاء غازيفا تحت إشراف طبيب متمرس في هذا العلاج على شكل قطرات عبر محلول وريدي على مدار عدة ساعات.</strong></p><p dir="rtl"><strong>علاج غازيفا:</strong></p><p dir="rtl"><strong>سرطان الدم الليمفاوي المزمن:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>يتم إعطاؤك 6 دورات علاجية من غازيفا مقترنا بدواء آخر لعلاج السرطان يسمى كلورامبوسيل.&nbsp; وتستمر كل دورة لمدة 28 يوم.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>في اليوم الأول من الدورة الأولى للعلاج، يتم إعطاؤك جزء من أول جرعة قدره 100 مج ببطء شديد.&nbsp; وسوف يراقبك الطبيب أو التمريض بعناية شديدة لمعرفة ظهور أي من أعراض الحساسية المفرطة المتعلقة بالمحلول.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>في حالة عدم ظهور أي من الأعراض بعد تناول الجزء الصغير من جرعتك الأولى، فقد يتم إعطاؤك باقي الجرعة الأولى (900 مج) في نفس اليوم.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>في حالة ظهور أي من أعراض فرط الحساسية تجاه المحلول بعد تناول الجزء الصغير من جرعتك الأولى، فسوف يتم إعطاؤك باقي الجرعة الأولى في اليوم الثاني.</strong></p></li></ul><p><br />&nbsp;</p><p dir="rtl"><strong>وفيما يلي الجدول النموذجي للجرعات:</strong></p><p dir="rtl"><strong>الدورة الأولى &ndash; تشمل ثلاثة جرعات من غازيفا كل 28 يوم:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>اليوم الأول &ndash; جزء من الجرعة الأولى (100 مج).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>اليوم الثاني أو اليوم الأول (مستمر) &ndash; باقي الجرعة الأولى (900) مج.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>اليوم الثامن &ndash; جرعة كاملة (1000 مج).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>اليوم الخامس عشر &ndash; جرعة كاملة (1000 مج).</strong></p></li></ul><p dir="rtl"><strong>الدورة الثانية والثالثة والرابعة والخامسة والسادسة تكون عبارة عن جرعة واحدة من غازيفا كل 28 يوم:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>اليوم الأول &ndash; جرعة كاملة (1000 مج).</strong></p></li></ul><p dir="rtl"><strong>سرطان الغدد الليمفاوية الجريبي:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>سوف يتم إعطاؤك 6 أو 8 دورات علاجية من غازيفا مقترنا بالأدوية الأخرى لعلاج السرطان، وتستمر كل دورة لمدة 28 يوم أو 21 يوم طبقا لنوعية أدوية السرطان الأخرى التي يتم إعطاؤها مع غازيفا.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تكون هذه المرحلة &quot;مرحلة الحث&quot; متبوعة بمرحلة أخرى تسمى &quot;مرحلة المداومة&quot; &ndash; وخلال هذه الفترة يتم إعطاؤك غازيفا كل شهرين لمدة تصل إلى عامين طالما لم يحدث أي تدرج في المرض.&nbsp; وبناء على حالتك المرضية بعد دورة العلاج الأولى، فسوف يقرر الطبيب إعطاؤك العلاج في مرحلة المداومة.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>فيما يلي الجدول النموذجي:</strong></p></li></ul><p dir="rtl"><strong>مرحلة الحث:</strong></p><p dir="rtl"><strong>الدورة الأولى &ndash; تشمل ثلاثة جرعات من غازيفا كل 28 يوم أو 21 يوم طبقا لنوعية أدوية السرطان الأخرى التي يتم إعطاؤها مع غازيفا:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>اليوم الأول &ndash; الجرعة الأولى (1000) مج.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>اليوم الثامن &ndash; جرعة كاملة (1000 مج).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>اليوم الخامس عشر &ndash; جرعة كاملة (1000 مج).</strong></p></li></ul><p><br />&nbsp;</p><p dir="rtl"><strong>الدورة الثانية &ndash; السادسة أو الثانية - الثامنة تكون عبارة عن جرعة واحدة فقط من غازيفا كل 28 يوم أو 21 يوم طبقا لنوعية أدوية السرطان الأخرى التي يتم إعطاؤها مع غازيفا:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>اليوم الأول &ndash; جرعة كاملة (1000 مج).</strong></p></li></ul><p dir="rtl"><strong>مرحلة المداومة:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>جرعة كاملة (1000 مج) كل شهرين لمدة عامين طالما لم يحدث أي تدرج في المرض.</strong></p></li></ul><p dir="rtl"><strong>الأدوية التي يتم إعطاؤها قبل كل محلول:</strong></p><p dir="rtl"><strong>قبل كل محلول من غازيفا، يتم إعطاؤك أوية أخرى لتقليل فرصة حدوث أي أعراض للحساسية المفرطة المتعلقة بالمحلول أو متلازمة تحلل الورم.&nbsp; وقد تشمل هذه الأدوية:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>السوائل</strong></p></li><li dir="rtl"><p dir="rtl"><strong>أدوية تخفيف الحمى</strong></p></li><li dir="rtl"><p dir="rtl"><strong>أدوية تخفيف الألم (المسكنات)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>أدوية تخفيف الالتهاب (الكورتيزونات)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>أدوية تخفيف الحساسية (مضادات الهيستامين)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>أدوية الوقاية من متلازمة تحلل الورم (مثل ألوبورينول)</strong></p></li></ul><p dir="rtl"><strong>في حالة الجرعة الفائتة من غازيفا:</strong></p><p dir="rtl"><strong>في حالة الجرعة الفائتة من غازيفا، يجب الحصول على موعد آخر في أقرب وقت ممكن.&nbsp; وهذا للمحافظة على جدول الجرعات اللازم لفاعلية الدواء.</strong></p><p dir="rtl"><strong>يجب استشارة الطبيب أو التمريض في حالة وجود أي تساؤلات أخرى عن استخدام هذا الدواء.</strong></p><p dir="rtl"><strong>إيقاف تناول غازيفا:</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>هذا الدواء مثله مثل أي دواء آخر من الممكن أن يسبب آثار جانبية ولكنها لا تحدث لجميع الأشخاص.&nbsp; وفيما يلي الآثار الجانبية التي قد تحدث لك مع استخدام هذا الدواء:</strong></p><p><br />&nbsp;</p><p dir="rtl"><strong>الآثار الجانبية الخطيرة:</strong></p><p dir="rtl"><strong>الحساسية المفرطة المتعلقة بالمحلول:</strong></p><p dir="rtl"><strong>يجب عليك إبلاغ الطبيب أو التمريض على الفور في حالة حدوث أي من الأعراض التالية أثناء حقن المحلول أو لمدة 24 ساعة بعد المحلول:</strong></p><p dir="rtl"><strong>الأعراض الأكثر شيوعا:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>الغثيان</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التعب</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الدوار</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الصداع</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الإسهال</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الحمى أو الاحمرار أو الرعشة</strong></p></li><li dir="rtl"><p dir="rtl"><strong>القىء</strong></p></li><li dir="rtl"><p dir="rtl"><strong>قصر النفس</strong></p></li><li dir="rtl"><p dir="rtl"><strong>انخفاض أو ارتفاع ضغط الدم</strong></p></li><li dir="rtl"><p dir="rtl"><strong>سرعة ضربات القلب</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم و ضيق الصدر</strong></p></li></ul><p dir="rtl"><strong>الأعراض الأقل شيوعا:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>عدم انتظام ضربات القلب</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تورم الحلق أو مجرى الهواء</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الصفير، صعوبة التنفس، ضيق الصدر، تهيج الحلق</strong></p></li></ul><p dir="rtl"><strong>يجب عليك إبلاغ الطبيب أو التمريض على الفور في حالة حدوث أي من هذه الأعراض.</strong></p><p><br />&nbsp;</p><p dir="rtl"><strong>اعتلال بيضاء الدماغ متعدد البؤر التقدمي:</strong></p><p dir="rtl"><strong>اعتلال بيضاء الدماغ متعدد البؤر التقدمي هو عبارة عن عدوى نادرة جدا في المخ مسببة للوفاة تم تسجيلها مع غازيفا.</strong></p><p dir="rtl"><strong>يجب عليك إبلاغ الطبيب أو التمريض على الفور في حالة ظهور أي من الأعراض التالية:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>فقدان الذاكرة</strong></p></li><li dir="rtl"><p dir="rtl"><strong>مشكلات في الكلام</strong></p></li><li dir="rtl"><p dir="rtl"><strong>صعوبة في المشي</strong></p></li><li dir="rtl"><p dir="rtl"><strong>مشكلات في الإبصار</strong></p></li></ul><p dir="rtl"><strong>في حالة وجود أي من هذه الأعراض قبل العلاج باستخدام غازيفا، يجب عليك إبلاغ الطبيب على الفور إذا لوحظ أي تغيرات في هذه الأعراض.&nbsp; فقد تحتاج إلى الخضوع للعلاج الطبي.</strong></p><p dir="rtl"><strong>العدوى:</strong></p><p dir="rtl"><strong>قد تكون أكثر عرضة للعدوى أثناء وبعد العلاج باستخدام غازيفا.&nbsp; وغالبا ما تكون هذه الأعراض عبارة عن نزلات برد.&nbsp; ولكن توجد حالات أخرى تشمل الإصابة بعدوى خطيرة.&nbsp; وتم تسجيل أيضا حالات من الإصابة بالفيروس الكبدي ب التي عادوت الظهور لدى المرضى الذين سبق لهم الإصابة بهذا المرض.</strong></p><p dir="rtl"><strong>يجب عليك إبلاغ الطبيب أو التمريض على الفور في حالة ظهور أي من آثار العدوى أثناء وبعد العلاج باستخدام غازيفا.&nbsp; وتشمل هذه الأعراض:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>الحمى</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الكحة</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم في الصدر</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التعب</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الطفح الجلدي المؤلم</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التهاب الحلق</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم وحرقة أثناء التبول</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الشعور بالتعب أو الإعياء العام</strong></p></li></ul><p dir="rtl"><strong>يجب عليك إبلاغ الطبيب في حالة تكرار حدوث العدوى أو وجود عدوى مزمنة قبل بدء العلاج باستخدام غازيفا.</strong></p><p dir="rtl"><strong>الآثار الجانبية الأخرى:</strong></p><p dir="rtl"><strong>أخبر طبيبك في حالة ملاحظة أي من الآثار الجانبية التالية:</strong></p><p dir="rtl"><strong>آثار جانبية شائعة جدا (قد تحدث لأكثر من شخص من بين كل عشرة أشخاص):</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>الحمى</strong></p></li><li dir="rtl"><p dir="rtl"><strong>العدوى الرئوية</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الصداع</strong></p></li><li dir="rtl"><p dir="rtl"><strong>آلام المفاصل والظهر</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الشعور بالضعف</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الإسهال، الإمساك</strong></p></li><li dir="rtl"><p dir="rtl"><strong>اضطراب النوم</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تساقط الشعر، الحكة</strong></p></li><li dir="rtl"><p dir="rtl"><strong>عدوى القناة البولية، التهاب الأنف والحلق، الحزام الناري</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التغيرات في نتائج تحاليل الدم وتشمل:</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الأنيميا (انخفاض مستويات خلايا الدم الحمراء)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>انخفاض مستويات جميع أنواع خلايا الدم البيضاء (مقترنة)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>انخفاض مستويات العدلات (نوع من خلايا الدم البيضاء)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>انخفاض مستويات الصفائح الدموية (التي تساعد الدم على التخثر)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>عدوى الجهاز التنفسي العلوي (الأنف، البلعوم، الحنجرة، الجيوب الأنفية)، الكحة</strong></p></li></ul><p dir="rtl"><strong>آثار جانبية شائعة (قد تحدث لشخص واحد من كل عشرة أشخاص):</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>احمرار العين</strong></p></li><li dir="rtl"><p dir="rtl"><strong>القروح الباردة</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الاكتئاب، القلق</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التعرق الليلي</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الأنفلونزا</strong></p></li><li dir="rtl"><p dir="rtl"><strong>فقدان الوزن</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم العقد الليمفاوية</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ارتشاح أو انسداد الأنف</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الإكزيما</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التهاب الأنف أو الحلق</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم في الفم أو الحلق</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم في العضلات أو العظام في منطقة الصدر</strong></p></li><li dir="rtl"><p dir="rtl"><strong>سرطان الجلد (سرطان الخلايا الحرشفية)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم في العظام، الذراعين، الرجلين</strong></p></li><li dir="rtl"><p dir="rtl"><strong>عدم انتظام ضربات القلب (الرجفان الأذيني)، الأزمة القلبية</strong></p></li><li dir="rtl"><p dir="rtl"><strong>مشكلات في التبول، سلس بولي</strong></p></li><li dir="rtl"><p dir="rtl"><strong>مشكلات في الهضم (مثل حرقة المعدة)، التهاب الأمعاء، البواسير</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تغيرات واضحة في نتائج تحاليل الدم:</strong></p></li><li dir="rtl"><p dir="rtl"><strong>انخفاض مستويات الخلايا اللميفاوية (نوع من خلايا الدم البيضاء)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>زيادة مستويات البوتاسيوم أو الفوسفات أو حمض اليوريك مما قد يسبب مشكلات في الكلى (جزء من متلازمة تحلل الورم)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>انخفاض مستويات البوتاسيوم</strong></p></li></ul><p dir="rtl"><strong>آثار جانبية غير شائعة (قد تحدث لشخص واحد من بين كل مائة شخص):</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>&nbsp;ثقب في المعدة أو الأمعاء وبالأخص في الحالات التي يؤثر فيها الورم في القنوات الهضمية.</strong></p></li></ul><p dir="rtl"><strong>يجب عليك إبلاغ الطبيب أو التمريض في حالة ملاحظة أي من الآثار الجانبية المذكورة أعلاه.</strong></p><p><br />&nbsp;</p><p dir="rtl"><strong>تسجيل الآثار الجانبية:</strong></p><p dir="rtl"><strong>في حالة حدوث أي من الآثار الجانبية، تحدث إلى الطبيب أو الصيدلي أو طاقم التمريض.&nbsp; وهذا يشمل أية آثار جانبية غير مذكورة في هذه النشرة.&nbsp; ومن خلال تسجيل الآثار الجانبية، يمكنك المساعدة في التزويد بالمزيد من المعلومات عن سلامة هذا الدواء.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>يخزن غازيفا من قبل متخصصي الرعاية الصحية بالمستشفى أو العيادة.&nbsp; وفيما يلي تفاصيل التخزين:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>يحفظ هذا الدواء بعيدا عن متناول الأطفال.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>لا يستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الخارجية.&nbsp; ويشير تاريخ الانتهاء إلى اليوم الأخير من الشهر.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يخزن في الثلاجة (2 &ndash; 8 درجة مئوية) ولا يجمد.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تحفظ الحاوية في العبوة الكرتون الخارجية لحمايتها من الضوء.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يجب عدم التخلص من الدواء في مياه الصرف أو المخلفات المنزلية.&nbsp; اسألي الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مستخدمة.&nbsp; وهذه التدابير سوف تساعدك على حماية البيئة</strong></p></li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>يحتوي عقار غازيفا على:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>المادة الفعالة أوبينوتوزوماب:&nbsp; 1000 مج / 40 مل لكل قارورة مركزة قبل التخفيف بمعدل 25 مج / مل.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>والعناصر الأخرى هي: إل &ndash; هيستيدين هيدروكلوريد مونوهيدرات، ثنائي هيدرات تريهالوز، بولوكسامير 188، ماء للحقن.</strong></p></li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>شكل عقار غازيفا ومحتويات العبوة:</strong></p><p dir="rtl"><strong>غازيفا محلول مركز للحقن عديم اللون مائل إلى البني الخفيف.&nbsp; ومتوفر غازيفا في عبوة تحتوي على قارورة زجاجية واحدة.</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>إف. هوفمان &ndash; لا روش المحدودة،</strong></p><p dir="rtl"><strong>124 جرينزاشيرستراس، سي إتش &ndash; 4070 بازل، سويسرا.</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر تحديث لهذه النشرة بتاريخ أكتوبر 2017.
لتسجيل أي آثار جانبية:
المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية (إن بي سي)
فاكس:  7662-205-11-966+
هاتف:  2038222-11-966+ داخلي:  2317 – 2356 – 2353 – 2354 – 2334 – 2340
الهاتف المجاني:  8002490000
البريد الإلكتروني:  npc.drug@sfda.gov.sa
الموقع على الإنترنت:  www.sfda.gov.sa/npc 

دول الخليج الأخرى:
يرجى الاتصال بالجهة المختصة.
مجلس وزراء الصحة العرب:
هذا الدواء:
هذا الدواء منتج يؤثر على صحتك واستهلاكه بطريقة مخالفة للتعليمات يعرض حياتك للخطر.
اتبع إرشادات الطبيب وطريقة الاستخدام وتعليمات الصيدلي الذي باع لك هذا الدواء.
الطبيب والصيدلي هم خبراء في الأدوية وفوائدها ومخاطرها.
لا تتوقف من تلقاء نفسك عن العلاج الموصوف لك.
لا تكرر نفس الوصفة الطبية من تلقاء نفسك دون استشارة الطبيب.
تحفظ جميع الأدوية بعيدا عن متناول الأطفال.

مجلس وزراء الصحة العرب
اتحاد الصيادلة العرب

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gazyva 1,000 mg concentrate for solution for infusion.

Black Box Warning:
WARNING: HEPATITIS B VIRUS REACTIVATION AND PROGRESSIVE MULTIGOCAL LEUKOENCEPHALOPATHY

Hepatitis B Virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients receiving CD20-directed cytolytic antibodies, including Gazyva. Screen all patients for HBV infection before treatment initiation. Monitor HBV-positive patients during and after treatment with Gazyva. Discontinue Gazyva and concomitant medications in the event of HBV reactivation.

Progressive Multifocal Leukoencephalopathy (PML) including fatal PML can occur in patients receiving Gazyva.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial of 40 mL concentrate contains 1,000 mg obinutuzumab, corresponding to a concentration before dilution of 25 mg/mL. 

Obinutuzumab is a Type II humanised anti-CD20 monoclonal antibody of the IgG1 subclass derived by humanisation of the parental B-Ly1 mouse antibody and produced in the Chinese Hamster Ovary cell line by recombinant DNA technology.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.

Clear, colourless to slightly brownish liquid.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Chronic Lymphocytic Leukaemia (CLL)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Gazyva in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy (see section 5.1).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Follicular Lymphoma (FL)&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Gazyva in combination with chemotherapy, followed by Gazyva maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma. (see section 5.1)</strong></p><p><br /><strong>Gazyva&nbsp;in&nbsp;combination with bendamustine&nbsp;followed by Gazyva&nbsp;maintenance&nbsp;is indicated for the treatment of patients with&nbsp;follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Gazyva should be administered under the close supervision of an experienced physician and in an environment where full resuscitation facilities are immediately available.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Posology</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Prophylaxis and premedication for tumour lysis syndrome (TLS)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients with a high tumour burden and/or a high circulating lymphocyte count (&gt;&nbsp;25&nbsp;x&nbsp;109/L) and/or renal impairment (CrCl &lt; 70 mL/min) are considered at risk of TLS and should receive prophylaxis. Prophylaxis should consist of adequate hydration and administration of uricostatics (e.g.&nbsp;allopurinol), or suitable alternative treatment such as urate oxidase (e.g. rasburicase), starting 1224&nbsp;hours prior to start of Gazyva infusion as per standard practice (see section 4.4). Patients should continue to receive repeated prophylaxis prior to each subsequent infusion, if deemed appropriate.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Prophylaxis and premedication for infusion related reactions (IRRs)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Premedication to reduce the risk of infusion related reactions is outlined in Table 1 (see also section 4.4). Corticosteroid premedication is recommended for patients with FL and mandatory for CLL patients in the first cycle (see Table 1). Premedication for subsequent infusions and other premedication should be administered as described below.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hypotension, as a symptom of IRRs, may occur during Gazyva intravenous infusions. Therefore, withholding of antihypertensive treatments should be considered for 12&nbsp;hours prior to and throughout each Gazyva infusion and for the first hour after administration (see section 4.4).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 1 Premedication to be administered before Gazyva infusion to reduce the risk of IRRs in patients with CLL and FL(see section 4.4)</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Day of treatment cycle</strong></p></td><td><p dir="ltr"><strong>Patients requiring premedication</strong></p></td><td><p dir="ltr"><strong>Premedication</strong></p></td><td><p dir="ltr"><strong>Administration</strong></p></td></tr><tr><td rowspan="3"><p dir="ltr"><strong>Cycle 1:</strong></p><p dir="ltr"><strong>Day 1 for CLL and FL</strong></p></td><td rowspan="3"><p dir="ltr"><strong>All patients</strong></p></td><td><p dir="ltr"><strong>Intravenous corticosteroid1,4</strong></p><p dir="ltr"><strong>(mandatory for CLL, recommended for FL)&nbsp;&nbsp;</strong></p></td><td><p dir="ltr"><strong>Completed at least 1&nbsp;hour prior to Gazyva infusion</strong></p></td></tr><tr><td><p dir="ltr"><strong>Oral analgesic/anti-pyretic2&nbsp;</strong></p></td><td rowspan="2"><p dir="ltr"><strong>At least 30&nbsp;minutes before Gazyva infusion</strong></p></td></tr><tr><td><p dir="ltr"><strong>Anti-histaminic medicine3&nbsp;</strong></p></td></tr><tr><td rowspan="3"><p dir="ltr"><strong>Cycle 1:</strong></p><p dir="ltr"><strong>Day 2 for CLL only</strong></p></td><td rowspan="3"><p dir="ltr"><strong>All patients</strong></p></td><td><p dir="ltr"><strong>Intravenous corticosteroid1</strong></p><p dir="ltr"><strong>(mandatory)&nbsp;&nbsp;</strong></p></td><td><p dir="ltr"><strong>Completed at least 1&nbsp;hour prior to Gazyva infusion&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Oral analgesic/anti-pyretic2&nbsp;</strong></p></td><td rowspan="2"><p dir="ltr"><strong>At least 30&nbsp;minutes before Gazyva infusion</strong></p></td></tr><tr><td><p dir="ltr"><strong>Anti-histaminic medicine3&nbsp;</strong></p></td></tr><tr><td rowspan="4"><p dir="ltr"><strong>All subsequent infusions for CLL and FL</strong></p><br />&nbsp;</td><td><p dir="ltr"><strong>Patients with no IRR during the previous infusion</strong></p></td><td><p dir="ltr"><strong>Oral analgesic/anti-pyretic2</strong></p></td><td rowspan="2"><p dir="ltr"><strong>At least 30&nbsp;minutes before Gazyva infusion</strong></p></td></tr><tr><td><p dir="ltr"><strong>Patients with an IRR (Grade 1 or 2) with the previous infusion</strong></p></td><td><p dir="ltr"><strong>Oral analgesic/anti-pyretic2</strong></p><p dir="ltr"><strong>Anti-histaminic medicine3&nbsp;</strong></p></td></tr><tr><td rowspan="2"><p dir="ltr"><strong>Patients with a Grade 3 IRR with the previous infusion OR<br />Patients with lymphocyte counts &gt;25&nbsp;x&nbsp;109/L prior to next treatment</strong></p></td><td><p dir="ltr"><strong>Intravenous corticosteroid1,4</strong></p><p dir="ltr"><strong>&nbsp;</strong></p></td><td><p dir="ltr"><strong>Completed at least 1&nbsp;hour prior to Gazyva infusion</strong></p></td></tr><tr><td><p dir="ltr"><strong>Oral analgesic/anti-pyretic2</strong></p><p dir="ltr"><strong>Anti-histaminic medicine3</strong></p></td><td><p dir="ltr"><strong>At least 30&nbsp;minutes before Gazyva infusion</strong></p></td></tr></tbody></table><p dir="ltr"><strong>1100&nbsp;mg prednisone/prednisolone or 20&nbsp;mg dexamethasone or 80&nbsp;mg methylprednisolone. Hydrocortisone should not be used as it has not been effective in reducing rates of IRR.</strong></p><p dir="ltr"><strong>2 e.g. 1,000&nbsp;mg acetaminophen/paracetamol</strong></p><p dir="ltr"><strong>3 e.g. 50&nbsp;mg diphenhydramine</strong></p><p dir="ltr"><strong>4.If a corticosteroid-containing chemotherapy regimen is administered on the same day as Gazyva, the corticosteroid can be administered as an oral medication if given at least 60 minutes prior to Gazyva, in which case additional IV corticosteroid as premedication is not required.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Dose</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Chronic lymphocytic leukaemia (CLL, in combination with chlorambucil1)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For patients with CLL the recommended dose of Gazyva in combination with chlorambucil is shown in Table 2.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Cycle 1</strong></p><p dir="ltr"><strong>The recommended dose of Gazyva in combination with chlorambucil is 1,000&nbsp;mg administered over Day&nbsp;1 and Day 2, (or Day 1 continued), and on&nbsp;Day&nbsp;8 and Day&nbsp;15 of the first 28&nbsp;day treatment cycle.&nbsp;</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Two infusion bags should be prepared for the infusion on Days&nbsp;1 and 2 (100&nbsp;mg for Day&nbsp;1 and 900&nbsp;mg for Day&nbsp;2). If the first bag is completed without modifications of the infusion rate or interruptions, the second bag may be administered on the same day (no dose delay necessary,&nbsp;no repetition of premedication), provided that appropriate time, conditions and medical supervision are available throughout the infusion. If there are any modifications of the infusion rate or interruptions during the first 100&nbsp;mg the second bag must be administered the following day.&nbsp;</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Cycles&nbsp;2&nbsp;-&nbsp;6</strong></p><p dir="ltr"><strong>The recommended dose of Gazyva in combination with chlorambucil is 1,000&nbsp;mg administered&nbsp;on Day&nbsp;1 of each cycle.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 2 Dose of Gazyva to be administered during 6&nbsp;treatment cycles each of 28&nbsp;days duration for patients with CLL</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Cycle</strong></p></td><td><p dir="ltr"><strong>Day of treatment</strong></p></td><td><p dir="ltr"><strong>Dose of Gazyva</strong></p></td></tr><tr><td rowspan="4"><p dir="ltr"><strong>Cycle&nbsp;1</strong></p></td><td><p dir="ltr"><strong>Day&nbsp;1</strong></p></td><td><p dir="ltr"><strong>100&nbsp;mg</strong></p></td></tr><tr><td><p dir="ltr"><strong>Day&nbsp;2</strong></p><p dir="ltr"><strong>(or Day&nbsp;1 continued)</strong></p></td><td><p dir="ltr"><strong>900&nbsp;mg</strong></p></td></tr><tr><td><p dir="ltr"><strong>Day&nbsp;8</strong></p></td><td><p dir="ltr"><strong>1,000&nbsp;mg</strong></p></td></tr><tr><td><p dir="ltr"><strong>Day&nbsp;15</strong></p></td><td><p dir="ltr"><strong>1,000&nbsp;mg</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cycles&nbsp;26</strong></p></td><td><p dir="ltr"><strong>Day&nbsp;1</strong></p></td><td><p dir="ltr"><strong>1,000&nbsp;mg</strong></p></td></tr></tbody></table><p dir="ltr"><strong>1See section 5.1 for information on chlorambucil dose</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Duration of treatment</strong></p><p dir="ltr"><strong>Six treatment cycles, each of 28&nbsp;day duration.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Delayed or missed doses</strong></p><p dir="ltr"><strong>If a planned dose of Gazyva is missed, it should be administered as soon as possible; do not wait until the next planned dose. The planned treatment interval for Gazyva should be maintained between doses.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Follicular lymphoma&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For patients with FL, the recommended dose of Gazyva in combination with chemotherapy is shown in Table 3.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients with previously untreated follicular lymphoma&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Induction (in combination with chemotherapy2)</strong></p><p dir="ltr"><strong>Gazyva should be administered with chemotherapy as follows:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Six 28-day cycles in combination with bendamustine2 or,</strong></p><p dir="ltr"><strong>∙ Six 21-day cycles in combination with cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP), followed by 2 additional cycles of Gazyva alone or,</strong></p><p dir="ltr"><strong>∙ Eight 21-day cycles in combination with cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone(CVP).&nbsp;</strong></p><p><br />&nbsp;</p><p dir="ltr"><strong>Maintenance&nbsp;</strong></p><p dir="ltr"><strong>Patients who achieve a complete or partial response to induction treatment with Gazyva in combination with chemotherapy (CHOP or CVP or bendamustine) should continue to receive Gazyva 1,000 mg as single agent maintenance therapy once every 2 months for 2 years or until disease progression (whichever occurs first).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Induction (in combination with bendamustine2)</strong></p><p dir="ltr"><strong>Gazyva should be administered in six 28-day cycles in combination with bendamustine2.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Maintenance&nbsp;</strong></p><p dir="ltr"><strong>Patients who achieved a complete or partial response to induction treatment (i.e. the initial 6 treatment cycles) with Gazyva in combination with bendamustine or have stable disease should continue to receive Gazyva 1,000 mg as single agent maintenance therapy once every 2 months for 2 years or until disease progression (whichever occurs first).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 3 Follicular lymphoma: Dose of Gazyva to be administered during induction treatment, followed by maintenance treatment&nbsp;</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Cycle</strong></p></td><td><p dir="ltr"><strong>Day of treatment</strong></p></td><td><p dir="ltr"><strong>Dose of Gazyva</strong></p></td></tr><tr><td rowspan="3"><p dir="ltr"><strong>Cycle 1</strong></p></td><td><p dir="ltr"><strong>Day 1</strong></p></td><td><p dir="ltr"><strong>1,000 mg</strong></p></td></tr><tr><td><p dir="ltr"><strong>Day 8</strong></p></td><td><p dir="ltr"><strong>1,000 mg</strong></p></td></tr><tr><td><p dir="ltr"><strong>Day 15</strong></p></td><td><p dir="ltr"><strong>1,000 mg</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cycles 2&ndash;6<br />or 2&ndash;8</strong></p></td><td><p dir="ltr"><strong>Day 1</strong></p></td><td><p dir="ltr"><strong>1,000 mg</strong></p></td></tr><tr><td><p dir="ltr"><strong>Maintenance&nbsp;</strong></p></td><td><p dir="ltr"><strong>Every 2 months for 2 years or until disease progression (whichever occurs first)</strong></p></td><td><p dir="ltr"><strong>1,000 mg</strong></p></td></tr></tbody></table><p dir="ltr"><strong>2See section 5.1 for information on bendamustine dose</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Duration of treatment</strong></p><p dir="ltr"><strong>Induction treatment of approximately six months (six treatment cycles of Gazyva, each of 28&nbsp;day duration when combined with bendamustine, or eight treatment cycles of Gazyva, each of 21&nbsp;day duration when combined with CHOP or CVP) followed by maintenance once every 2 months for 2 years or until disease progression (whichever occurs first).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Delayed or missed doses&nbsp;</strong></p><p dir="ltr"><strong>If a planned dose of Gazyva is missed, it should be administered as soon as possible; do not omit it or wait until the next planned dose.&nbsp;</strong></p><p dir="ltr"><strong>If toxicity occurs before Cycle 1 Day 8 or Cycle 1 Day 15, requiring delay of treatment, these doses should be given after resolution of toxicity. In such instances, all subsequent visits and the start of Cycle 2 will be shifted to accommodate for the delay in Cycle 1.&nbsp;</strong></p><p dir="ltr"><strong>During maintenance, maintain the original dosing schedule for subsequent doses.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Dose modifications during treatment (all indications)</strong></p><p dir="ltr"><strong>No dose reductions of Gazyva are recommended.&nbsp;</strong></p><p dir="ltr"><strong>For management of symptomatic adverse events (including IRRs), see paragraph below (Management of IRRs or section 4.4).</strong></p><p><br /><br /><br />&nbsp;</p><p dir="ltr"><strong>Special populations</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elderly&nbsp;</strong></p><p dir="ltr"><strong>No dose adjustment is required in elderly patients (see section 5.2).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Renal impairment</strong></p><p dir="ltr"><strong>No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance [CrCl] 3089&nbsp;mL/min) (see section 5.2). The safety and efficacy of Gazyva has not been established in patients with severe renal impairment (CrCl &lt;&nbsp;30&nbsp;mL/min) (see sections 4.8 and 5.2).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hepatic impairment&nbsp;</strong></p><p dir="ltr"><strong>The safety and efficacy of Gazyva in patients with impaired hepatic function has not been established. No specific dose recommendations can be made.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population</strong></p><p dir="ltr"><strong>The safety and efficacy of Gazyva in children and adolescents aged below 18&nbsp;years has not been established. No data are available.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Method of administration</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Gazyva is for intravenous use. It should be given as an intravenous infusion through a dedicated line after dilution (see section 6.6). Gazyva infusions should not be administered as an intravenous push or bolus.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For instructions on dilution of Gazyva before administration, see section 6.6.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Instructions on the rate of infusion are shown in Tables 4-5.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 4 Chronic lymphocytic leukaemia: Standard infusion rate in the absence of IRRs/hypersensitivity and recommendations in case an IRR occurred with previous infusion&nbsp;</strong></p><p>&nbsp;</p><table><tbody><tr><td colspan="2"><p dir="ltr"><strong>Cycle</strong></p></td><td><p dir="ltr"><strong>Day of treatment</strong></p></td><td><p dir="ltr"><strong>Rate of infusion&nbsp;</strong></p><p dir="ltr"><strong>The infusion rate may be escalated provided that the patient can tolerate it. For management of IRRs that occur during the infusion, refer to &ldquo;Management of IRRs&rdquo;.</strong></p></td></tr><tr><td rowspan="4"><p dir="ltr"><strong>Cycle&nbsp;1</strong></p></td><td colspan="2"><p dir="ltr"><strong>Day&nbsp;1&nbsp;</strong></p><p dir="ltr"><strong>(100&nbsp;mg)</strong></p></td><td><p dir="ltr"><strong>Administer at 25&nbsp;mg/hr over 4&nbsp;hours. Do not increase the infusion rate.</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Day&nbsp;2&nbsp;</strong></p><p dir="ltr"><strong>(or Day&nbsp;1 continued)&nbsp;</strong></p><p dir="ltr"><strong>(900&nbsp;mg)</strong></p></td><td><p dir="ltr"><strong>If no IRR occurred during the previous infusion, administer at 50&nbsp;mg/hr.<br />The rate of the infusion can be escalated in increments of 50&nbsp;mg/hr every 30 minutes to a maximum rate of 400&nbsp;mg/hr.</strong></p>&nbsp;<p dir="ltr"><strong>If the patient experienced an IRR during the previous infusion, start with administration at 25 mg/hr. The rate of infusion can be escalated in increments up to 50 mg/hr every 30 minutes to a maximum rate of 400 mg/hr.&nbsp;</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Day&nbsp;8</strong></p><p dir="ltr"><strong>(1,000 mg)</strong></p></td><td rowspan="3"><p dir="ltr"><strong>If no IRR occurred during the previous infusion, when the final infusion rate was 100 mg/hr or faster, infusions can be started at a rate of 100&nbsp;mg/hr and increased by 100&nbsp;mg/hr increments every 30&nbsp;minutes to a maximum of 400&nbsp;mg/hr.</strong></p><p dir="ltr"><strong>If the patient experienced an IRR during the previous infusion administer at 50 mg/hr. The rate of the infusion can be escalated in increments of 50 mg/hr every 30 minutes to a maximum rate of 400 mg/hr.</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Day&nbsp;15</strong></p><p dir="ltr"><strong>(1,000 mg)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cycles 26</strong></p></td><td colspan="2"><p dir="ltr"><strong>Day&nbsp;1</strong></p><p dir="ltr"><strong>(1,000 mg)</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>Table 5 Follicular lymphoma: Standard infusion rate in the absence of IRRs /hypersensitivity and recommendations in case an IRR occurred with previous infusion</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Cycle</strong></p></td><td><p dir="ltr"><strong>Day of treatment</strong></p></td><td><p dir="ltr"><strong>Rate of infusion&nbsp;</strong></p><p dir="ltr"><strong>The infusion rate may be escalated provided that the patient can tolerate it. For management of IRRs that occur during the infusion, refer to &ldquo;Management of IRRs&rdquo;.&nbsp;</strong></p></td></tr><tr><td rowspan="3"><p dir="ltr"><strong>Cycle 1</strong></p></td><td><p dir="ltr"><strong>Day 1</strong></p><p dir="ltr"><strong>(1,000 mg)</strong></p></td><td><p dir="ltr"><strong>Administer at 50 mg/hr. The rate of infusion can be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.</strong></p></td></tr><tr><td><p dir="ltr"><strong>Day 8</strong></p><p dir="ltr"><strong>(1,000 mg)</strong></p></td><td rowspan="4"><p dir="ltr"><strong>If no IRR or if an IRR Grade 1 occurred during the previous infusion when the final infusion rate was 100 mg/hr or faster, infusions can be started at a rate of 100 mg/hr and increased by 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.</strong></p>&nbsp;<p dir="ltr"><strong>If the patient experienced an IRR of Grade 2 or higher during the previous infusion administer at 50 mg/hr. The rate of infusion can be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.</strong></p></td></tr><tr><td><p dir="ltr"><strong>Day 15</strong></p><p dir="ltr"><strong>(1,000 mg)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cycles 2&ndash;6 or 2&ndash;8</strong></p></td><td><p dir="ltr"><strong>Day 1</strong></p><p dir="ltr"><strong>(1,000 mg)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Maintenance</strong></p></td><td><p dir="ltr"><strong>Every 2 months for 2 years or until disease progression (whichever occurs first)&nbsp;</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>Management of IRRs (all indications)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Management of IRRs may require temporary interruption, reduction in the rate of infusion, or treatment discontinuations of Gazyva as outlined below (see also section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Grade&nbsp;4 (life threatening): Infusion must be stopped and therapy must be permanently discontinued.</strong></p><p dir="ltr"><strong>∙ Grade&nbsp;3 (severe): Infusion must be temporarily stopped and symptoms treated. Upon resolution of symptoms, the infusion can be restarted at no more than half the previous rate (the rate being used at the time that the IRR occurred) and, if the patient does not experience any IRR symptoms, the infusion rate escalation can resume at the increments and intervals as appropriate for the treatment dose (see Tables 4 and 5). For CLL patients receiving the Day&nbsp;1 (Cycle&nbsp;1) dose split over two days, the Day 1 infusion rate may be increased back up to 25&nbsp;mg/hr after 1&nbsp;hour, but not increased further.&nbsp;</strong></p><p dir="ltr"><strong>The infusion must be stopped and therapy permanently discontinued if the patient experiences a second occurrence of a Grade&nbsp;3 IRR.</strong></p><p dir="ltr"><strong>∙ Grade&nbsp;12 (mild to moderate): The infusion rate must be reduced and symptoms treated. Infusion can be continued upon resolution of symptoms and, if the patient does not experience any IRR symptoms, the infusion rate escalation can resume at the increments and intervals as appropriate for the treatment dose (see Tables&nbsp;4 and 5). For CLL patients receiving the Day&nbsp;1 (Cycle&nbsp;1) dose split over the two days, the Day 1 infusion rate may be increased back up to 25&nbsp;mg/hr after 1&nbsp;hour, but not increased further.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>In order to improve the traceability of biological medicinal products, the trade name and batch number of the administered product should be clearly recorded (or stated) in the patient file.&nbsp;</strong></p><p dir="ltr"><strong>Based on a subgroup analysis in previously untreated follicular lymphoma, the efficacy in FLIPI low risk (0-1) patients is currently inconclusive (see section 5.1). A therapy choice for these patients should carefully consider the overall safety profile of Gazyva plus chemotherapy and the patient-specific situation.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Infusion Related Reactions&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The most frequently observed adverse drug reactions (ADRs) in patients receiving Gazyva were IRRs, which occurred predominantly during infusion of the first 1,000&nbsp;mg. IRRs may be related to cytokine release syndrome which has also been reported in Gazyva treated patients. In CLL patients who received the combined measures for prevention of IRRs (adequate corticosteroid, oral analgesic/anti-histamine, omission of antihypertensive medicine in the morning of the first infusion, and the Cycle&nbsp;1 Day&nbsp;1 dose administered over 2&nbsp;days) as described in section 4.2, a decreased incidence of IRRs of all Grades was observed. The rates of Grade 34 IRRs (which were based on a relatively small number of patients) were similar before and after mitigation measures were implemented. Mitigation measures to reduce IRRs should be followed (see section 4.2). The incidence and severity of infusion related symptoms decreased substantially after the first 1,000&nbsp;mg was infused, with most patients having no IRRs during subsequent administrations of Gazyva (see section 4.8).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the majority of patients, irrespective of indication, IRRs were mild to moderate and could be managed by the slowing or temporary halting of the first infusion, but severe and lifethreatening IRRs requiring symptomatic treatment have also been reported. IRRs may be clinically indistinguishable from immunoglobulin E (IgE) mediated allergic reactions (e.g. anaphylaxis). Patients with a high tumour burden and/or high circulating lymphocyte count in CLL [&gt;&nbsp;25&nbsp;x&nbsp;109/L] may be at increased risk of severe IRRs. Patients with renal impairment (CrCl &lt;&nbsp;50&nbsp;mL/min) and patients with both Cumulative Illness Rating Scale (CIRS) &gt;&nbsp;6 and CrCl &lt;&nbsp;70&nbsp;mL/min are more at risk of IRRs, including severe IRRs (see section 4.8). For management of IRRs see section 4.2 Posology and method of administration.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients must not receive further Gazyva infusions if they experience:&nbsp;</strong></p><p dir="ltr"><strong>∙ acute life-threatening respiratory symptoms,&nbsp;</strong></p><p dir="ltr"><strong>∙ a Grade&nbsp;4 (i.e. life threatening) IRR or,&nbsp;</strong></p><p dir="ltr"><strong>∙ a second occurrence of a Grade&nbsp;3 (prolonged/recurrent) IRR (after resuming the first infusion or during a subsequent infusion).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients who have pre-existing cardiac or pulmonary conditions should be monitored carefully throughout the infusion and the post-infusion period. Hypotension may occur during Gazyva intravenous infusions. Therefore, withholding of antihypertensive treatments should be considered for 12&nbsp;hours prior to and throughout each Gazyva infusion and for the first hour after administration. Patients at acute risk of hypertensive crisis should be evaluated for the benefits and risks of withholding their anti-hypertensive medicine.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hypersensitivity reactions&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hypersensitivity reactions with immediate (e.g.&nbsp; anaphylaxis) and delayed onset (e.g. serum sickness) have been reported in patients treated with Gazyva. Hypersensitivity may be difficult to clinically distinguish from infusion related reactions. Hypersensitivity symptoms can occur after previous exposure and very rarely with the first infusion. If a hypersensitivity reaction is suspected during or after an infusion, the infusion must be stopped and treatment permanently discontinued. Patients with known hypersensitivity to obinutuzumab must not be treated (see section 4.3).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Tumour lysis syndrome (TLS)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Tumour lysis syndrome (TLS) has been reported with Gazyva. Patients who are considered to be at risk of TLS (e.g. patients with a high tumour burden and/or a high circulating lymphocyte count [&gt;&nbsp;25&nbsp;x&nbsp;109/L] and/or renal impairment [CrCl &lt; 70 mL/min]) should receive prophylaxis. Prophylaxis should consist of adequate hydration and administration of uricostatics (e.g.&nbsp;allopurinol), or a suitable alternative such as a urate oxidate (e.g. rasburicase) starting 1224 hours prior to the infusion of Gazyva as per standard practice (see section 4.2). All patients considered at risk should be carefully monitored during the initial days of treatment with a special focus on renal function, potassium, and uric acid values. Any additional guidelines according to standard practice should be followed. For treatment of TLS, correct electrolyte abnormalities, monitor renal function and fluid balance, and administer supportive care, including dialysis as indicated.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Neutropenia&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Severe and life-threatening neutropenia including febrile neutropenia has been reported during treatment with Gazyva. Patients who experience neutropenia should be closely monitored with regular laboratory tests until resolution. If treatment is necessary it should be administered in accordance with local guidelines and the administration of granulocyte-colony stimulating factors (G-CSF) should be considered. Any signs of concomitant infection should be treated as appropriate. Dose delays should be considered in case of severe or life-threatening neutropenia. It is strongly recommended that patients&nbsp;with severe neutropenia lasting more than 1 week receive antimicrobial prophylaxis throughout the treatment period until resolution to Grade 1 or 2. Antiviral and antifungal prophylaxis should also be considered (see section 4.2). Late onset neutropenia (occurring &gt;28&nbsp;days after the end of treatment) or prolonged neutropenia (lasting more than 28&nbsp;days after treatment has been completed/stopped) may occur. Patients with renal impairment (CrCl &lt;&nbsp;50&nbsp;mL/min) are more at risk of neutropenia (see section 4.8).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Thrombocytopenia</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Severe and life-threatening thrombocytopenia including acute thrombocytopenia (occurring within 24&nbsp;hours after the infusion) has been observed during treatment with Gazyva. Patients with renal impairment (CrCl &lt;&nbsp;50&nbsp;mL/min) are more at risk of thrombocytopenia (see section 4.8). Fatal haemorrhagic events have also been reported in Cycle&nbsp;1 in patients treated with Gazyva. A clear relationship between thrombocytopenia and haemorrhagic events has not been established.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients should be closely monitored for thrombocytopenia, especially during the first cycle; regular laboratory tests should be performed until the event resolves, and dose delays should be considered in case of severe or life-threatening thrombocytopenia. Transfusion of blood products (i.e. platelet transfusion) according to institutional practice is at the discretion of the treating physician. Use of any concomitant therapies which could possibly worsen thrombocytopenia-related events, such as platelet inhibitors and anticoagulants, should also be taken into consideration, especially during the first cycle.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Worsening of pre-existing cardiac conditions</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In patients with underlying cardiac disease, arrhythmias (such as atrial fibrillation and tachyarrhythmia), angina pectoris, acute coronary syndrome, myocardial infarction and heart failure have occurred when treated with Gazyva (see section 4.8). These events may occur as part of an IRR and can be fatal. Therefore patients with a history of cardiac disease should be monitored closely. In addition these patients should be hydrated with caution in order to prevent a potential fluid overload.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Infections</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Gazyva should not be administered in the presence of an active infection and caution should be exercised when considering the use of Gazyva in patients with a history of recurring or chronic infections.&nbsp; Serious bacterial, fungal, and new or reactivated viral infections can occur during and following the completion of Gazyva therapy. Fatal infections have been reported.&nbsp;</strong></p><p dir="ltr"><strong>Patients (CLL) with both CIRS &gt;&nbsp;6 and CrCl &lt;&nbsp;70&nbsp;mL/min are more at risk of infections, including severe infections (see section 4.8). In the follicular lymphoma studies, a high incidence of infections was observed in all phases of the studies, including follow-up, with the highest incidence seen in the maintenance phase. During the follow-up phase, Grade 3-5 infections are observed more in patients who received Gazyva plus bendamustine in the induction phase.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hepatitis B reactivation&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, can occur in patients treated with antiCD20 antibodies including Gazyva (see section 4.8). HBVscreening should be performed in all patients before initiation of treatment with Gazyva. At a minimum this should include hepatitis B surface antigen (HBsAg) status and hepatitis B core antibody (HBcAb) status. These can be complemented with other appropriate markers as per local guidelines. Patients with active hepatitis B disease should not be treated with Gazyva. Patients with positive hepatitis B serology should consult liver disease experts before start of treatment and should be monitored and managed following local medical standards to prevent hepatitis reactivation.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Progressive multifocal leukoencephalopathy (PML)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Progressive multifocal leukoencephalopathy (PML) has been reported in patients treated with Gazyva (see section 4.8). The diagnosis of PML should be considered in any patient presenting with new-onset or changes to pre-existing neurologic manifestations. The symptoms of PML are nonspecific and can vary depending on the affected region of the brain. Motor symptoms with corticospinal tract findings (e.g. muscular weakness, paralysis and sensory disturbances), sensory abnormalities, cerebellar symptoms, and visual field defects are common. Some signs/symptoms regarded as &ldquo;cortical&rdquo; (e.g. aphasia or visual-spatial disorientation) may occur. Evaluation of PML includes, but is not limited to, consultation with a neurologist, brain magnetic resonance imaging (MRI), and lumbar puncture (cerebrospinal fluid testing for John Cunningham viral DNA). Therapy with Gazyva should be withheld during the investigation of potential PML and permanently discontinued in case of confirmed PML. Discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy should also be considered. The patient should be referred to a neurologist for the evaluation and treatment of PML.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Immunisation</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The safety of immunisation with live or attenuated viral vaccines following Gazyva therapy has not been studied and vaccination with live virus vaccines is not recommended during treatment and until B-cell recovery.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Exposure in utero to obinutuzumab and vaccination of infants with live virus vaccines</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Due to the potential depletion of B-cells in infants of mothers who have been exposed to Gazyva during pregnancy, infants should be monitored for B-cell depletion and vaccinations with live virus vaccines should be postponed until the infant&rsquo;s B-cell count has recovered.&nbsp; The safety and timing of vaccination should be discussed with the infant&rsquo;s physician (see section 4.6).</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>No formal drug-drug interaction studies have been performed, although limited drug-drug interaction sub-studies have been undertaken for Gazyva with bendamustine, CHOP, fludarabine and cyclophosphamide (FC), and chlorambucil.&nbsp;</strong></p><p dir="ltr"><strong>A risk for interactions with other concomitantly used medicinal products cannot be excluded.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pharmacokinetic interactions</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Obinutuzumab is not a substrate, inhibitor, or inducer of cytochrome P450 (CYP450), uridine diphosphate glucuronyltransferase (UGT) enzymes and transporters such as P-glycoprotein. Therefore, no pharmacokinetic interaction is expected with drugs known to be metabolised by these enzyme systems.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Co-administration with Gazyva had no effect on the pharmacokinetics of bendamustine, FC, chlorambucil or the individual components of CHOP. In addition, there were no apparent effects of bendamustine, FC, chlorambucil or CHOP on the pharmacokinetics of Gazyva.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pharmacodynamic interactions</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Vaccination with live virus vaccines is not recommended during treatment and until B-cell recovery because of the immunosuppressive effect of obinutuzumab (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The combination of obinutuzumab with chlorambucil, bendamustine, CHOP or CVP may increase the risk of neutropenia (see section 4.4).</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Women of childbearing potential</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Women of childbearing potential must use effective contraception during and for 18 months after treatment with Gazyva.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pregnancy</strong></p><p>&nbsp;</p><p dir="ltr"><strong>A reproduction study in cynomolgus monkeys showed no evidence of embryofoetal toxicity or teratogenic effects but resulted in a complete depletion of B-lymphocytes in offspring. B-cell counts returned to normal levels in the offspring, and immunologic function was restored within 6 months of birth. Serum concentrations of obinutuzumab in offspring were similar to those in the mothers on day&nbsp;28 post-partum, whereas concentrations in milk on the same day were very low, suggesting that obinutuzumab crosses the placenta (see section 5.3). There are no data from the use of obinutuzumab in pregnant women. Gazyva should not be administered to pregnant women unless the possible benefit outweighs the potential risk.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In case of exposure during pregnancy, depletion of B-cells may be expected in infants due to the pharmacological properties of the product. Postponing vaccination with live vaccines should be considered for infants born to mothers who have been exposed to Gazyva during pregnancy until the infant&rsquo;s B-cell levels are within normal ranges (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Breast-feeding</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Animal studies have shown secretion of obinutuzumab in breast milk (see section 5.3).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Since human immunoglobulin G (IgG) is secreted in human milk and the potential for absorption and harm to the infant is unknown, women should be advised to discontinue breast-feeding during Gazyva therapy and for 18&nbsp;months after the last dose of Gazyva.</strong></p><p dir="ltr"><strong>Fertility</strong></p><p>&nbsp;</p><p dir="ltr"><strong>No specific studies in animals have been performed to evaluate the effect of obinutuzumab on fertility. No adverse effects on male and female reproductive organs were observed in repeat-dose toxicity studies in cynomolgus monkeys (see section 5.3).</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Gazyva has no or negligible influence on the ability to drive and use machines. IRRs are very common during the first infusion of Gazyva, and patients experiencing infusion related symptoms should be advised not to drive or use machines until symptoms abate.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Summary of the safety profile</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The adverse drug reactions (ADRs) described in this section were identified during induction, maintenance and follow up for indolent Non-Hodgkin lymphoma (iNHL) including FL; treatment and follow up for CLL in the three pivotal clinical studies:</strong></p><p dir="ltr"><strong>∙ BO21004/CLL11 (N=781): Patients with previously untreated CLL</strong></p><p dir="ltr"><strong>∙ BO21223/GALLIUM (N=1390): Patients with previously untreated iNHL (86% of the patients had FL)</strong></p><p dir="ltr"><strong>∙ GAO4753g/GADOLIN (N=392): Patients with iNHL (81% of the patients had FL) who had no response to or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>These trials investigated Gazyva in combination with chlorambucil for CLL and with bendamustine, CHOP or CVP followed by Gazyva maintenance therapy for iNHL. The studies BO21223/GALLIUM and GAO4753g/GADOLIN enrolled patients with iNHL including FL. Therefore, in order to provide the most comprehensive safety information, the analysis of ADRs presented in the following has been performed on the entire study population (i.e. iNHL).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 6 summarises the ADRs of the pivotal studies (BO21004/CLL11, BO21223/GALLIUM GAO4753g/GADOLIN) that occurred at a higher incidence (difference of &ge; 2%) compared to the relevant comparator arm in at least one pivotal study in:</strong></p><p dir="ltr"><strong>∙ Patients with CLL receiving Gazyva plus chlorambucil compared with chlorambucil alone or rituximab plus chlorambucil (study BO21004/CLL11)&nbsp;</strong></p><p dir="ltr"><strong>∙ Patients with previously untreated iNHL receiving Gazyva plus chemotherapy (bendamustine, CHOP, CVP) followed by Gazyva maintenance in patients achieving a response, compared to rituximab plus chemotherapy followed by rituximab maintenance in patients achieving a response (study BO21223/GALLIUM)</strong></p><p dir="ltr"><strong>∙ Patients with iNHL who had no response to or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen receiving Gazyva plus bendamustine, followed by Gazyva maintenance in some patients, compared to bendamustine alone (study GAO4753g/GADOLIN)&nbsp;</strong></p><p dir="ltr"><strong>The incidences presented in Table 6 (all grades and Grades 3-5) are the highest incidence of that ADR reported from any of the three studies.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Frequencies are defined as very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000) and very rare (&lt;&nbsp;1/10,000). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Tabulated list of adverse reactions</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 6 Summary of ADRs reported with a higher incidence (difference of &ge;2% versus the comparator arm) in patients# receiving Gazyva + chemotherapy*&nbsp;</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Frequency</strong></p></td><td><p dir="ltr"><strong>All Grades&nbsp;</strong></p><p dir="ltr"><strong>Gazyva + chemotherapy* (CLL, iNHL) followed by Gazyva maintenance (iNHL)</strong></p></td><td><p dir="ltr"><strong>Grades 3-5&dagger;&nbsp;</strong></p><p dir="ltr"><strong>Gazyva + chemotherapy* (CLL, iNHL) followed by Gazyva maintenance (iNHL)</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Infections and infestations</strong></p></td></tr><tr><td><p dir="ltr"><strong>Very common</strong></p></td><td><p dir="ltr"><strong>Upper respiratory tract infection, sinusitis&sect;, , urinary tract infection, pneumonia&sect; ,herpes zoster&sect;</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Oral herpes, rhinitis, pharyngitis, lung infection, influenza nasopharyngitis</strong></p></td><td><p dir="ltr"><strong>Urinary tract infection, pneumonia, lung infection, upper respiratory tract infection, sinusitis, herpes zoster</strong></p></td></tr><tr><td><p dir="ltr"><strong>Uncommon</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Nasopharyngitis, rhinitis, influenza, oral herpes</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Squamous cell carcinoma of skin</strong></p></td><td><p dir="ltr"><strong>Squamous cell carcinoma of skin</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Very common</strong></p></td><td><p dir="ltr"><strong>Neutropenia&sect;, thrombocytopenia, anaemia, leukopenia</strong></p></td><td><p dir="ltr"><strong>Neutropenia, thrombocytopenia&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Lymph node pain</strong></p></td><td><p dir="ltr"><strong>Anaemia, leukopenia</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Tumour lysis syndrome, hyperuricaemia, hypokalaemia</strong></p></td><td><p dir="ltr"><strong>Tumour lysis syndrome, hypokalaemia</strong></p></td></tr><tr><td><p dir="ltr"><strong>Uncommon</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Hyperuricaemia</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Nervous system disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Very common</strong></p></td><td><p dir="ltr"><strong>Headache</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Uncommon</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Headache</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Psychiatric disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Very common</strong></p></td><td><p dir="ltr"><strong>Insomnia</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Depression, anxiety</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Uncommon</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Insomnia, depression, anxiety</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Eye disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Ocular hyperaemia</strong></p></td><td>&nbsp;</td></tr><tr><td colspan="3"><p dir="ltr"><strong>Cardiac disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Atrial fibrillation, cardiac failure</strong></p></td><td><p dir="ltr"><strong>Atrial fibrillation, cardiac failure,&nbsp;</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Vascular disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Hypertension</strong></p></td><td><p dir="ltr"><strong>Hypertension</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Very common</strong></p></td><td><p dir="ltr"><strong>Cough&sect;</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Nasal congestion, rhinorrhoea, oropharyngeal pain</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Uncommon</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Cough, oropharyngeal pain</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Very common</strong></p></td><td><p dir="ltr"><strong>Diarrhoea, constipation&sect;</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Dyspepsia, colitis, haemorrhoids</strong></p></td><td><p dir="ltr"><strong>Diarrhoea, colitis</strong></p></td></tr><tr><td><p dir="ltr"><strong>Uncommon</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Constipation, haemorrhoids</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Very common</strong></p></td><td><p dir="ltr"><strong>Alopecia, pruritus</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Night sweats, eczema</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Uncommon</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Pruritus, night sweats</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Very common</strong></p></td><td><p dir="ltr"><strong>Arthralgia&sect;, back pain</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Musculoskeletal chest pain, pain in extremity, bone pain</strong></p></td><td><p dir="ltr"><strong>Pain in extremity</strong></p></td></tr><tr><td><p dir="ltr"><strong>Uncommon</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Arthralgia, back pain, musculoskeletal chest pain, bone pain</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Renal and Urinary Disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common&nbsp;</strong></p></td><td><p dir="ltr"><strong>Dysuria, urinary incontinence</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Uncommon</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Dysuria, urinary incontinence</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td><p dir="ltr"><strong>Very common</strong></p></td><td><p dir="ltr"><strong>Pyrexia, Asthenia</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Chest pain</strong></p></td><td><p dir="ltr"><strong>Pyrexia, asthenia</strong></p></td></tr><tr><td><p dir="ltr"><strong>Uncommon</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Chest pain</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Investigations</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>White blood cell count decreased, neutrophil count decreased, weight increased</strong></p></td><td><p dir="ltr"><strong>White blood cell count decreased, neutrophil count decreased</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Injury, poisoning and procedural complications</strong></p></td></tr><tr><td><p dir="ltr"><strong>Very common</strong></p></td><td><p dir="ltr"><strong>IRRs&nbsp;</strong></p></td><td><p dir="ltr"><strong>IRRs&nbsp;</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>#with a higher incidence (difference of &ge; 2% between the treatment arms). Only the highest frequency observed in the trials is reported (based on studies BO21004/previously untreated CLL, BO21223/previously untreated advanced iNHL and GAO4753g/rituximab refractory iNHL)</strong></p><p dir="ltr"><strong>&dagger; No Grade 5 adverse reactions have been observed with a difference of &ge;&nbsp;2% between the treatment arms</strong></p><p dir="ltr"><strong>* Chemotherapy: Chlorambucil in CLL; bendamustine, CHOP, CVP in iNHL including FL</strong></p><p dir="ltr"><strong>&sect; observed also during maintenance treatment with at least 2% higher incidence in Gazyva arm (BO21223)</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>In study GAO4753g/GADOLIN, patients in the bendamustine arm received 6 months of induction treatment only, whereas after the induction period, patients in the Gazyva plus bendamustine arm continued with Gazyva maintenance treatment.</strong></p><p dir="ltr"><strong>During the maintenance period in study GAO4753g/GADOLIN, the most common adverse reactions were cough (15%), upper respiratory infections (12%), neutropenia (11%), sinusitis (10%), diarrhoea (8%), IRRs (8%), nausea (8%), fatigue (8%), bronchitis (7%), arthralgia (7%), pyrexia (6%), nasopharyngitis (6%), and urinary tract infections (6%). The most common Grade 3-5 adverse reactions were neutropenia (10%), and anaemia, febrile neutropenia, thrombocytopenia, sepsis, upper respiratory tract infection, and urinary tract infection (all at 1%).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The profile of adverse reactions in patients with FL was consistent with the overall iNHL population in both studies.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Description of selected adverse reactions</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The incidences presented in the following sections if referring to iNHL are the highest incidence of that ADR reported from either pivotal study (BO21223/GALLIUM, GAO4753g/GADOLIN).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Infusion related reactions </strong><br />&nbsp;</p><p dir="ltr"><strong>Most frequently reported (&ge; 5%) symptoms associated with an IRR were nausea, vomiting, diarrhoea, headache, dizziness, fatigue, chills, pyrexia, hypotension, flushing, hypertension, tachycardia, dyspnoea, and chest discomfort. Respiratory symptoms such as bronchospasm, larynx and throat irritation, wheezing, laryngeal oedema and cardiac symptoms such as atrial fibrillation have also been reported (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Chronic Lymphocytic Leukaemia&nbsp;</strong></p><p dir="ltr"><strong>The incidence of IRRs was higher in the Gazyva plus chlorambucil arm compared to the rituximab plus chlorambucil arm. The incidence of IRRs was 65% with the infusion of the first 1,000&nbsp;mg of Gazyva (20% of patients experiencing a Grade 34 IRR). Overall, 7% of patients experienced an IRR leading to discontinuation of Gazyva. The incidence of IRRs with subsequent infusions was 3% with the second 1,000&nbsp;mg dose and 1% thereafter. No Grade 35 IRRs were reported beyond the first 1,000&nbsp;mg infusions of Cycle&nbsp;1.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In patients who received the recommended measures for prevention of IRRs as described in section 4.2, a decreased incidence of IRRs of all Grades was observed. The rates of Grade 3-4 IRRs (which occurred in relatively few patients) were similar before and after mitigation measures were implemented.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Indolent Non-Hodgkin Lymphoma including Follicular Lymphoma&nbsp;</strong></p><p dir="ltr"><strong>Grade 3-4 IRRs occurred in 12% of patients. In Cycle 1, the overall incidence of IRRs was higher in patients receiving Gazyva plus chemotherapy compared to patients in the comparator arm. In patients receiving Gazyva plus chemotherapy, the incidence of IRRs was highest on Day 1 and gradually decreased with subsequent infusions. This decreasing trend continued during maintenance therapy with Gazyva alone. Beyond Cycle 1 the incidence of IRRs in subsequent infusions was comparable between the Gazyva and the relevant comparator arms. Overall, 3% of patients experienced an infusion related reaction leading to discontinuation of Gazyva.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Neutropenia and infections</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Chronic Lymphocytic Leukaemia</strong></p><p dir="ltr"><strong>The incidence of neutropenia was higher in the Gazyva plus chlorambucil arm (41%) compared to the rituximab plus chlorambucil arm with the neutropenia resolving spontaneously or with use of granulocyte-colony stimulating factors. The incidence of infection was 38% in the Gazyva plus chlorambucil arm and 37% in the rituximab plus chlorambucil arm (with Grade 35 events reported in 12% and 14%, respectively and fatal events reported in &lt;&nbsp;1% in both treatment arms). Cases of prolonged neutropenia (2% in the Gazyva plus chlorambucil arm and 4% in the rituximab plus chlorambucil arm) and late onset neutropenia (16% in the Gazyva plus chlorambucil arm and 12% in the rituximab plus chlorambucil arm) were also reported (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Indolent Non-Hodgkin Lymphoma including Follicular Lymphoma&nbsp;</strong></p><p dir="ltr"><strong>In the Gazyva plus chemotherapy arm, the incidence of Grade 1-4 neutropenia (50%) was higher relative to the comparator arm with an increased risk during the induction period. The incidence of prolonged neutropenia and late onset neutropenia was 3% and 7%, respectively. The incidence of infection was 81% in the Gazyva plus chemotherapy arm (with Grade 3-5 events reported in 22% of patients and fatal events reported in 3% of patients). Patients who received G-CSF prophylaxis had a lower rate of Grade 3-5 infections (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Thrombocytopenia and haemorrhagic events</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Chronic Lymphocytic Leukaemia</strong></p><p dir="ltr"><strong>The incidence of thrombocytopenia was higher in the Gazyva plus chlorambucil arm (15%) compared to the rituximab plus chlorambucil arm especially during the first cycle. Four percent of patients treated with Gazyva plus chlorambucil experienced acute thrombocytopenia (occurring within 24&nbsp;hours after the Gazyva infusion) (see section 4.4). The overall incidence of haemorrhagic events was similar in the Gazyva treated arm and in the rituximab treated arm. The number of fatal haemorrhagic events was balanced between the treatment arms; however, all of the events in patients treated with Gazyva were reported in Cycle&nbsp;1. A clear relationship between thrombocytopenia and haemorrhagic events has not been established.</strong></p><p><br /><br />&nbsp;</p><p dir="ltr"><strong>Indolent Non-Hodgkin Lymphoma including Follicular Lymphoma&nbsp;</strong></p><p dir="ltr"><strong>The incidence of thrombocytopenia was 14%. Thrombocytopenia occurred more frequently in Cycle 1 in the Gazyva plus chemotherapy arm. Thrombocytopenia occurring during or 24 hours from end of infusion (acute thrombocytopenia) was more frequently observed in patients in the Gazyva plus chemotherapy arm than in the comparator arm. The incidence of haemorrhagic events was similar across all treatment arms. Haemorrhagic events and Grade 3-5 haemorrhagic events occurred in 12% and 5% of patients, respectively. While fatal haemorrhagic events occurred in less than 1% of patients; none of the fatal adverse events occurred in Cycle 1.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Special populations</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elderly</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Chronic Lymphocytic Leukaemia</strong></p><p dir="ltr"><strong>In the pivotal BO21004/CLL11 study, 46% (156&nbsp;out of&nbsp;336) of patients with CLL treated with Gazyva plus chlorambucil were 75&nbsp;years or older (median age was 74&nbsp;years). These patients experienced more serious adverse events and adverse events leading to death than those patients &lt;&nbsp;75&nbsp;years of age.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Indolent Non Hodgkin Lymphoma including Follicular Lymphoma</strong></p><p dir="ltr"><strong>In the pivotal studies (BO21223/GALLIUM, GAO4753g/GADOLIN) in iNHL, patients 65 years or older experienced more serious adverse events and adverse events leading to withdrawal or death than patients &lt; 65 years of age.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Renal impairment</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Chronic Lymphocytic Leukaemia</strong></p><p dir="ltr"><strong>In the pivotal BO21004/CLL11 study, 27% (90&nbsp;out of&nbsp;336) of patients treated with Gazyva plus chlorambucil had moderate renal impairment (CrCl &lt;&nbsp;50&nbsp;mL/min). These patients experienced more serious adverse events and adverse events leading to death than patients with a CrCl &ge; 50&nbsp;mL/min (see&nbsp;section 4.2, 4.4 and 5.2). Patients with a CrCl &lt; 30 mL/min were excluded from the study (see&nbsp;section 5.1).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Indolent Non Hodgkin Lymphoma including Follicular Lymphoma</strong></p><p dir="ltr"><strong>In the pivotal studies (BO21223/GALLIUM, GAO4753g/GADOLIN) in iNHL, 5% (35 out of 698) and 8% (15 out of 194) of patients treated with Gazyva, respectively, had moderate renal impairment (CrCL &lt; 50 mL/min). These patients experienced more serious adverse events, adverse events leading to death and adverse events leading to treatment withdrawal than patients with a CrCl &ge; 50 mL/min (see section 4.2 and 5.2). Patients with a CrCl &lt; 40 mL/min were excluded from the studies (see section 5.1).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Additional safety information from clinical studies experience</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Progressive multifocal leukoencephalopathy&nbsp;</strong></p><p dir="ltr"><strong>PML has been reported in patients treated with Gazyva (see section 4.4).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hepatitis B reactivation&nbsp;</strong></p><p dir="ltr"><strong>Cases of hepatitis B reactivation have been reported in patients treated with Gazyva (see&nbsp;section&nbsp;4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Gastro-Intestinal Perforation&nbsp;</strong></p><p dir="ltr"><strong>Cases of gastro-intestinal perforation have been reported in patients receiving Gazyva, mainly in iNHL. In the pivotal studies in iNHL up to 1% of patients experienced gastrointestinal perforation.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Worsening of pre-existing cardiac conditions</strong></p><p dir="ltr"><strong>Cases of arrhythmias (such as atrial fibrillation and tachyarrhythmia), angina pectoris, acute coronary syndrome, myocardial infarction and heart failure have occurred when treated with Gazyva (see section 4.4). These events may occur as part of an IRR and can be fatal.</strong></p><p dir="ltr"><strong>Laboratory abnormalities</strong></p><p dir="ltr"><strong>Transient elevation in liver enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase) has been observed shortly after the first infusion of Gazyva.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Reporting of suspected adverse reactions</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>To reports any side effect(s):</strong><br />&nbsp;</p><p dir="ltr"><strong>&bull;&nbsp; &nbsp; Saudi Arabia:</strong></p><table><tbody><tr><td><ul><li dir="ltr"><p dir="ltr"><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p></li></ul><ul><li dir="ltr"><p dir="ltr"><strong>Fax: +966-11-205-7662</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Toll free phone: 8002490000</strong></p></li><li dir="ltr"><p dir="ltr"><strong>E-mail: npc.drug@sfda.gov.sa</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Website: www.sfda.gov.sa/npc</strong></p></li></ul></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>&bull;&nbsp; &nbsp; Other GCC States:</strong></p><table><tbody><tr><td><ul><li dir="ltr"><p dir="ltr"><strong>Please contact the relevant competent authority.</strong></p></li></ul></td></tr></tbody></table><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>No experience with overdose is available from human clinical studies. In clinical studies with Gazyva, doses ranging from 50&nbsp;mg up to and including 2,000&nbsp;mg per infusion have been administered. The incidence and intensity of adverse reactions reported in these studies did not appear to be dose dependent.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients who experience overdose should have immediate interruption or reduction of their infusion and be closely supervised. Consideration should be given to the need for regular monitoring of blood cell count and for increased risk of infections while patients are B-cell depleted.</strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies, ATC code: L01XC15</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Mechanism of action</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Obinutuzumab is a recombinant monoclonal humanised and glycoengineered Type&nbsp;II antiCD20 antibody of the IgG1 isotype. It specifically targets the extracellular loop of the CD20 transmembrane antigen on the surface of non-malignant and malignant pre-B and mature B-lymphocytes, but not on haematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissue. Glycoengineering of the Fc part of obinutuzumab results in higher affinity for FcɣRIII receptors on immune effector cells such as natural killer (NK) cells, macrophages and monocytes as compared to non-glycoengineered antibodies.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In nonclinical studies, obinutuzumab induces direct cell death and mediates antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) through recruitment of FcɣRIII positive immune effector cells. In addition, in vivo, obinutuzumab mediates a low degree of complement dependent cytotoxicity (CDC). Compared to Type I antibodies, obinutuzumab, a Type II antibody, is characterised by an enhanced direct cell death induction with a concomitant reduction in CDC at an equivalent dose. Obinutuzumab, as a glycoengineered antibody, is characterised by enhanced ADCC and ADCP compared to non-glycoengineered antibodies at an equivalent dose. In animal models obinutuzumab mediates potent B-cell depletion and antitumour efficacy.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the pivotal clinical study BO21004/CLL11, 91% (40&nbsp;out of&nbsp;44) of evaluable patients treated with Gazyva were B-cell depleted (defined as CD19+ B-cell counts &lt;&nbsp;0.07&nbsp;x&nbsp;109/L) at the end of treatment period and remained depleted during the first 6&nbsp;months of follow up. Recovery of B-cells was observed within 1218&nbsp;months of follow up in 35% (14&nbsp;out of&nbsp;40) of patients without progressive disease and 13% (5&nbsp;out of&nbsp;40) with progressive disease.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Clinical efficacy and safety</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Chronic Lymphocytic Leukaemia</strong></p><p>&nbsp;</p><p dir="ltr"><strong>A Phase III international, multicentre, open label, randomised, two-stage, three-arm clinical study (BO21004/CLL11) investigating the efficacy and safety of Gazyva plus chlorambucil (GClb) compared to rituximab plus chlorambucil (RClb) or chlorambucil (Clb) alone was conducted in patients with previously untreated chronic lymphocytic leukaemia with comorbidities.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Prior to enrolment, patients had to have documented CD20+ CLL, and one or both of the following measures of coexisting medical conditions: comorbidity score (CIRS) of greater than&nbsp;6 or reduced renal function as measured by CrCl &lt; 70&nbsp;mL/min. Patients with inadequate liver function (National Cancer Institute &ndash; Common Terminology Criteria for Adverse Events Grade 3 liver function tests (AST, ALT &gt;&nbsp;5&nbsp;x&nbsp;ULN for &gt;&nbsp;2 weeks; bilirubin &gt;&nbsp;3&nbsp;x&nbsp;ULN) and renal function (CrCl &lt;&nbsp;30&nbsp;mL/min) were excluded. Patients with one or more individual organ/system impairment score of&nbsp;4 as assessed by the CIRS definition, excluding&nbsp;eyes, ears, nose, throat and larynx organ system, were excluded.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>A total of 781&nbsp;patients were randomised 2:2:1 to receive Gazyva plus chlorambucil, rituximab plus chlorambucil or chlorambucil alone. Stage&nbsp;1a compared Gazyva plus chlorambucil to chlorambucil alone in 356&nbsp;patients and Stage&nbsp;2 compared Gazyva plus chlorambucil to rituximab plus chlorambucil in 663&nbsp;patients. Efficacy results are summarised in Table&nbsp;7 and in Figures&nbsp;13.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the majority of patients, Gazyva was given intravenously as a 1,000&nbsp;mg initial dose administered on Day&nbsp;1, Day&nbsp;8 and Day&nbsp;15 of the first treatment cycle. In order to reduce the rate of infusion related reactions in patients, an amendment was implemented and 140&nbsp;patients received the first Gazyva dose administered over 2&nbsp;days (Day&nbsp;1 [100&nbsp;mg] and Day&nbsp;2 [900&nbsp;mg]) (see section 4.2 and 4.4). For each subsequent treatment cycle (Cycles&nbsp;2&nbsp;to&nbsp;6), patients received Gazyva 1,000&nbsp;mg on Day&nbsp;1 only. Chlorambucil was given orally at 0.5&nbsp;mg/kg body weight on Day&nbsp;1 and Day&nbsp;15 of all treatment cycles (1&nbsp;to&nbsp;6).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The demographics data and baseline characteristics were well balanced between the treatment arms. The majority of patients were Caucasian (95%) and male (61%). The median age was 73&nbsp;years, with 44% being 75&nbsp;years or older. At baseline, 22% of patients had Binet Stage A, 42% had Binet Stage B and 36% had Binet Stage C.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The median comorbidity score was&nbsp;8 and 76% of the patients enrolled had a comorbidity score above&nbsp;6. The median estimated CrCl was 62&nbsp;mL/min and 66% of all patients had a CrCl &lt;&nbsp;70&nbsp;mL/min. Forty-two percent of patients enrolled had both a CrCl &lt;&nbsp;70&nbsp;mL/min and a comorbidity score of &gt;&nbsp;6. Thirty-four percent of patients were enrolled on comorbidity score alone, and 23% of patients were enrolled with only impaired renal function.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The most frequently reported coexisting medical conditions (using a cut off of 30% or higher), in the MedDRA body systems are: Vascular disorders (73%), Cardiac disorders (46%), Gastrointestinal disorders (38%), Metabolism and nutrition disorders (40%), Renal and urinary disorders (38%), Musculoskeletal and connective tissue disorders (33%).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table&nbsp;7 Summary of efficacy from BO21004/CLL11 study</strong></p><table><tbody><tr><td>&nbsp;</td><td colspan="3"><p dir="ltr"><strong>Stage 1a</strong></p></td><td colspan="3"><p dir="ltr"><strong>Stage 2</strong></p></td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Chlorambucil</strong></p><p dir="ltr"><strong>N=118</strong></p></td><td colspan="2"><p dir="ltr"><strong>Gazyva + chlorambucil</strong></p><p dir="ltr"><strong>N= 238</strong></p></td><td colspan="2"><p dir="ltr"><strong>Rituximab + chlorambucil</strong></p><p dir="ltr"><strong>N= 330</strong></p></td><td><p dir="ltr"><strong>Gazyva + chlorambucil</strong></p><p dir="ltr"><strong>N= 333</strong></p></td></tr><tr><td>&nbsp;</td><td colspan="4"><p dir="ltr"><strong>22.8 months median observation time</strong></p></td><td colspan="2"><p dir="ltr"><strong>18.7 months median observation time</strong></p></td></tr><tr><td><p dir="ltr"><strong>Primary endpoint</strong></p></td><td colspan="4">&nbsp;</td><td colspan="2">&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Investigator-assessed PFS (PFS-INV)a</strong></p></td><td colspan="2">&nbsp;</td><td colspan="2">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Number (%) of patients with event&nbsp;</strong></p></td><td colspan="2"><p dir="ltr"><strong>96 (81.4%)</strong></p></td><td colspan="2"><p dir="ltr"><strong>93 (39.1%)</strong></p></td><td><p dir="ltr"><strong>199 (60.3%)</strong></p></td><td><p dir="ltr"><strong>104 (31.2%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median time to event (months)&nbsp;</strong></p></td><td colspan="2"><p dir="ltr"><strong>11.1</strong></p></td><td colspan="2"><p dir="ltr"><strong>26.7</strong></p></td><td><p dir="ltr"><strong>15.2</strong></p></td><td><p dir="ltr"><strong>26.7</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hazard ratio (95% CI)</strong></p></td><td colspan="4"><p dir="ltr"><strong>0.18 [0.13; 0.24]</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.39 [0.31; 0.49]</strong></p></td></tr><tr><td><p dir="ltr"><strong>p-value (Log-Rank test, stratifiedb)</strong></p></td><td colspan="4"><p dir="ltr"><strong>&lt; 0.0001</strong></p></td><td colspan="2"><p dir="ltr"><strong>&lt; 0.0001</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Key secondary endpoints</strong></p></td><td colspan="2">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>IRC-assessed PFS (PFS-IRC)a</strong></p></td><td colspan="2">&nbsp;</td><td colspan="2">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Number (%) of patients with event&nbsp;</strong></p></td><td colspan="2"><p dir="ltr"><strong>90 (76.3%)</strong></p></td><td colspan="2"><p dir="ltr"><strong>89 (37.4%)</strong></p></td><td><p dir="ltr"><strong>183 (55.5%)</strong></p></td><td><p dir="ltr"><strong>103 (30.9%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median time to event (months)&nbsp;</strong></p></td><td colspan="2"><p dir="ltr"><strong>11.2</strong></p></td><td colspan="2"><p dir="ltr"><strong>27.2</strong></p></td><td><p dir="ltr"><strong>14.9</strong></p></td><td><p dir="ltr"><strong>26.7</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hazard ratio (95% CI)</strong></p></td><td colspan="4"><p dir="ltr"><strong>0.19 [0.14; 0.27]</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.42 [0.33; 0.54]</strong></p></td></tr><tr><td><p dir="ltr"><strong>p-value (Log-Rank test, stratifiedb)</strong></p></td><td colspan="4"><p dir="ltr"><strong>&lt; 0.0001</strong></p></td><td colspan="2"><p dir="ltr"><strong>&lt; 0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>End of treatment response rate</strong></p></td><td>&nbsp;</td><td colspan="3">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>No. of patients included in the analysis</strong></p></td><td><p dir="ltr"><strong>118&nbsp;</strong></p></td><td colspan="3"><p dir="ltr"><strong>238&nbsp;</strong></p></td><td><p dir="ltr"><strong>329</strong></p></td><td><p dir="ltr"><strong>333</strong></p></td></tr><tr><td><p dir="ltr"><strong>Responders (%)</strong></p></td><td><p dir="ltr"><strong>37 (31.4%)</strong></p></td><td colspan="3"><p dir="ltr"><strong>184 (77.3%)</strong></p></td><td><p dir="ltr"><strong>214 (65.0%)</strong></p></td><td><p dir="ltr"><strong>261 (78.4%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Non-responders (%)</strong></p></td><td><p dir="ltr"><strong>81 (68.6%)</strong></p></td><td colspan="3"><p dir="ltr"><strong>54 (22.7%)</strong></p></td><td><p dir="ltr"><strong>115 (35.0%)</strong></p></td><td><p dir="ltr"><strong>72 (21.6%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Difference in response rate, (95% CI)</strong></p></td><td colspan="4"><p dir="ltr"><strong>45.95 [35.6; 56.3]</strong></p></td><td colspan="2"><p dir="ltr"><strong>13.33 [6.4; 20.3]</strong></p></td></tr><tr><td><p dir="ltr"><strong>p-value (Chi-squared Test)</strong></p></td><td colspan="4"><p dir="ltr"><strong>&lt; 0.0001</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>No. of complete respondersc (%)</strong></p></td><td colspan="2"><p dir="ltr"><strong>0 (0.0%)</strong></p></td><td colspan="2"><p dir="ltr"><strong>53 (22.3%)</strong></p></td><td><p dir="ltr"><strong>23 (7.0%)</strong></p></td><td><p dir="ltr"><strong>69 (20.7%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Molecular remission at end of treatmentd</strong></p></td><td colspan="2">&nbsp;</td><td colspan="2">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>No. of patients included in the analysis</strong></p></td><td colspan="2"><p dir="ltr"><strong>90&nbsp;</strong></p></td><td colspan="2"><p dir="ltr"><strong>168&nbsp;</strong></p></td><td><p dir="ltr"><strong>244</strong></p></td><td><p dir="ltr"><strong>239</strong></p></td></tr><tr><td><p dir="ltr"><strong>MRD negativee (%)</strong></p></td><td colspan="2"><p dir="ltr"><strong>0 (0%)</strong></p></td><td colspan="2"><p dir="ltr"><strong>45 (26.8%)</strong></p></td><td><p dir="ltr"><strong>6 (2.5%)</strong></p></td><td><p dir="ltr"><strong>61 (25.5%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>MRD positivef (%)</strong></p></td><td colspan="2"><p dir="ltr"><strong>90 (100%)</strong></p></td><td colspan="2"><p dir="ltr"><strong>123 (73.2%)</strong></p></td><td><p dir="ltr"><strong>238 (97.5%)</strong></p></td><td><p dir="ltr"><strong>178 (74.5%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Difference in MRD rates, (95% CI)</strong></p></td><td colspan="4"><p dir="ltr"><strong>26.79 [19.5; 34.1]</strong></p></td><td colspan="2"><p dir="ltr"><strong>23.06 [17.0; 29.1]</strong></p></td></tr><tr><td><p dir="ltr"><strong>Event free survival</strong></p></td><td>&nbsp;</td><td colspan="3">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>No. (%) of patients with event&nbsp;</strong></p></td><td><p dir="ltr"><strong>103 (87.3%)</strong></p></td><td colspan="3"><p dir="ltr"><strong>104 (43.7%)</strong></p></td><td><p dir="ltr"><strong>208 (63.0 %)</strong></p></td><td><p dir="ltr"><strong>118 (35.4 %)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median time to event (months)&nbsp;</strong></p></td><td><p dir="ltr"><strong>10.8</strong></p></td><td colspan="3"><p dir="ltr"><strong>26.1</strong></p></td><td><p dir="ltr"><strong>14.3</strong></p></td><td><p dir="ltr"><strong>26.1</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hazard ratio (95% CI)</strong></p></td><td colspan="4"><p dir="ltr"><strong>0.19 [0.14; 0.25]</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.43 [0.34; 0.54]</strong></p></td></tr><tr><td><p dir="ltr"><strong>p-value (Log-Rank test, stratifiedb)</strong></p></td><td colspan="4"><p dir="ltr"><strong>&lt; 0.0001</strong></p></td><td colspan="2"><p dir="ltr"><strong>&lt; 0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>Time to new anti-leukaemic therapy</strong></p></td><td>&nbsp;</td><td colspan="3">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>No. (%) of patients with event&nbsp;</strong></p></td><td><p dir="ltr"><strong>65 (55.1%)</strong></p></td><td colspan="3"><p dir="ltr"><strong>51 (21.4%)</strong></p></td><td><p dir="ltr"><strong>86 (26.1%)</strong></p></td><td><p dir="ltr"><strong>55 (16.5%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median time to event (months)&nbsp;</strong></p></td><td><p dir="ltr"><strong>14.8</strong></p></td><td colspan="3"><p dir="ltr"><strong>-</strong></p></td><td><p dir="ltr"><strong>30.8</strong></p></td><td><p dir="ltr"><strong>-</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hazard ratio (95% CI)</strong></p></td><td colspan="4"><p dir="ltr"><strong>0.24 [0.16; 0.35]</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.59 [0.42; 0.82]</strong></p></td></tr><tr><td><p dir="ltr"><strong>p-value (Log-Rank test, stratifiedb)</strong></p></td><td colspan="4"><p dir="ltr"><strong>&lt; 0.0001</strong></p></td><td colspan="2"><p dir="ltr"><strong>&lt; 0.0018</strong></p></td></tr><tr><td><p dir="ltr"><strong>Overall survival</strong></p></td><td>&nbsp;</td><td colspan="3">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>No. (%) of patients with event</strong></p></td><td><p dir="ltr"><strong>24 (20.3%)</strong></p></td><td colspan="3"><p dir="ltr"><strong>22 (9.2%)</strong></p></td><td><p dir="ltr"><strong>41 (12.4%)</strong></p></td><td><p dir="ltr"><strong>28 (8.4%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median time to event (months)</strong></p></td><td><p dir="ltr"><strong>NR</strong></p></td><td colspan="3"><p dir="ltr"><strong>NR</strong></p></td><td><p dir="ltr"><strong>NR**</strong></p></td><td><p dir="ltr"><strong>NR**</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hazard ratio (95% CI)</strong></p></td><td colspan="4"><p dir="ltr"><strong>0.41 [0.23; 0.74]</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.66 [0.41; 1.06] **</strong></p></td></tr><tr><td><p dir="ltr"><strong>p-value (Log-Rank test, stratifiedb)</strong></p></td><td colspan="4"><p dir="ltr"><strong>0.0022</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.0849**</strong></p></td></tr></tbody></table><p dir="ltr"><strong>IRC: Independent Review Committee; PFS: progression-free survival; HR: Hazard Ratio; CI: Confidence Intervals, MRD: Minimal Residual Disease</strong></p><p dir="ltr"><strong>a Defined as the time from randomisation to the first occurrence of progression, relapse or death from any cause as assessed by the investigator</strong></p><p dir="ltr"><strong>b stratified by Binet stage at baseline&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>c Includes 11 patients in the GClb arm with a complete response with incomplete marrow recovery</strong></p><p dir="ltr"><strong>d Blood and bone marrow combined</strong></p><p dir="ltr"><strong>e MRD negativity is defined as a result below 0.0001</strong></p><p dir="ltr"><strong>f Includes MRD positive patients and patients who progressed or died before the end of treatment</strong></p><p dir="ltr"><strong>NR = Not reached</strong></p><p dir="ltr"><strong>** Data not yet mature</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Overall survival (OS) for Stage&nbsp;1a is presented in Figure&nbsp;2. OSfor Stage&nbsp;2 will continue to be followed and is not yet mature. Results of the progression free survival (PFS) subgroup analysis (i.e. sex, age, Binet stages, CrCl, CIRS score, beta2-microglobulin, IGVH status, chromosomal abnormalities, lymphocyte count at baseline) were consistent with the results seen in the overall Intent-to-Treat population. The risk of disease progression or death was reduced in the GClb arm compared to the RClb arm and Clb arm in all subgroups except in the subgroup of patients with deletion 17p. In the small subgroup of patients with deletion&nbsp;17p, only a positive trend was observed compared to Clb (HR=0.42, p=0.0892); no benefit was observed compared to RClb. For subgroups, reduction of the risk of disease progression or death ranged from 92% to 58% for GClb versus Clb and 72% to 29% for GClb versus RClb.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Figure&nbsp;1 Kaplan-Meier curve of Investigator assessed PFSfrom Stage&nbsp;1a in patients with CLL (Study BO21004/CLL11)</strong></p><p dir="ltr"><strong><img width="443" height="332" src="https://lh6.googleusercontent.com/1Apcojam5zJFoRU5oIxLVCcFXDkboe2DzyqGja0nNzze6s54KlC2cLF5vGYnNMNESgmAQmwCfMkk_lFOaefIjVksBMDsUns7hOiFwERByYYM2OrZbGM1xEsOPBq7qxDk-9jB2LE" /></strong></p><p>&nbsp;</p><p dir="ltr"><strong>Figure&nbsp;2 Kaplan-Meier curve of OSfrom Stage&nbsp;1a in patients with CLL (Study BO21004/CLL11)</strong></p><p dir="ltr"><strong><img width="420" height="371" src="https://lh5.googleusercontent.com/-SrUfefxOOUkuIsVpmaeq4niB6pif_0p_PcmXkeSMQsNQRbrwtlh6dPuBK859q2Fa90DuzhZD18unwwWMrK2bt6RQVko9Xkq3pV254d5ik3uZB78BtD4Zwud4isuIHrwUbnNJ1Y" /></strong></p><p>&nbsp;</p><p dir="ltr"><strong>Figure&nbsp;3 Kaplan-Meier curve of investigator assessed PFSfrom Stage&nbsp;2 in patients with CLL (Study BO21004/CLL11)</strong></p><p dir="ltr"><strong><img width="437" height="333" src="https://lh5.googleusercontent.com/Y4lxvSjw9zX8zY46LXHF2zXagkQrLdTgkTNWaIF1le1oR0ZRWAmJPbEt4K6kubXG7tXbdGalTXCscgSm7OTGa4Mb39UWvpKzMjPdhPsUr-5nQE_AMfxQdAkpOwxOBHyEeAPgzD8" /></strong></p><p>&nbsp;</p><p dir="ltr"><strong>Quality of life</strong></p><p dir="ltr"><strong>In the QLQC30 and QLQ-CLL-16 questionnaires conducted during the treatment period, no substantial difference in any of the subscales was observed. Data during follow up, especially for the chlorambucil alone arm, is limited. However, no notable differences in quality of life during follow up have been identified to date.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Health-related quality of life assessments, specific to fatigue through treatment period, show no statistically significant difference suggesting that the addition of Gazyva to a chlorambucil regimen does not increase the experience of fatigue for patients.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Follicular lymphoma</strong></p><p dir="ltr"><strong>Previously untreated follicular lymphoma (study BO21223/GALLIUM)&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In a phase III, open label, multicentre, randomised clinical study (BO21223/GALLIUM), 1202&nbsp;patients with previously untreated Grade 1-3a advanced (stage II bulky disease, stage III/IV) FL were evaluated. Patients with FL Grade 3b were excluded from the study. Patients were randomised to 1:1 to receive either Gazyva (n=601 patients) or rituximab (n=601 patients) in combination with chemotherapy (bendamustine, CHOP or CVP), followed by Gazyva or rituximab maintenance in patients achieving a complete or partial response.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Gazyva was given by intravenous infusion as a dose of 1,000 mg on Days 1, 8 and 15 of Cycle 1, on Day 1 of subsequent cycles. In total, six cycles of Gazyva (every 28 days) were given in combination with six cycles of bendamustine, and a total of eight cycles of Gazyva (every 21 days) were given in combination with six cycles of CHOP or eight cycles of CVP. Gazyva was administered prior to chemotherapy. Bendamustine was given intravenously on Days 1 and 2 for all treatment cycles (Cycles 16) at 90 mg/m2/day when given in combination with Gazyva. Standard dosing of CHOP and CVP was given. Following Cycles 6-8, in combination with chemotherapy, responding patients received Gazyva maintenance therapy every 2 months until disease progression or for up to 2 years.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The demographic data and baseline characteristics of the patient population were well balanced between the treatment arms; median age was 59 years, 81% were Caucasian, 53% were female, 79% had a FLIPI score of &ge; 2 and 7% had Stage II (bulky), 35% had Stage III and 57% had Stage IV disease, 44% had bulky disease (&gt; 7 cm), 34% had at least one B-symptom at baseline and 97% had an ECOG performance status of 0-1 at baseline. Fifty-seven percent received bendamustine, 33% received CHOP, and 10% received CVP chemotherapy.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Efficacy results for patients with previously untreated FL are summarised in Table 8. Kaplan-Meier curves for progression-free survival (PFS) are shown in Figure 4.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 8 Summary of efficacy in patients with previously untreated FL from BO21223/ GALLIUM study</strong></p><p>&nbsp;</p><table><tbody><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Rituximab + Chemotherapy followed by rituximab maintenance</strong></p><p dir="ltr"><strong>N=601</strong></p></td><td><p dir="ltr"><strong>Gazyva +Chemotherapy followed by Gazyva maintenance</strong></p><p dir="ltr"><strong>N=601</strong></p></td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Median observation time 34&nbsp;months</strong></p></td><td><p dir="ltr"><strong>Median observation time 35&nbsp;months</strong></p></td></tr><tr><td><p dir="ltr"><strong>Primary Endpoint</strong></p></td><td colspan="2">&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Investigator-assessed PFS&sect; (PFS-INV)&nbsp;</strong></p></td><td colspan="2">&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Number (%) of patients with event&nbsp;</strong></p></td><td><p dir="ltr"><strong>144 (24.0%)</strong></p></td><td><p dir="ltr"><strong>101 (16.8%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>HR [95% CI]</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.66 [0.51, 0.85]</strong></p></td></tr><tr><td><p dir="ltr"><strong>p-value (Log-Rank test, stratified*)</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.0012</strong></p></td></tr><tr><td><p dir="ltr"><strong>3 year PFS estimate<br />[95% CI]</strong></p></td><td><p dir="ltr"><strong>73.3<br />[68.8, 77.2]</strong></p></td><td><p dir="ltr"><strong>80.0<br />[75.9, 83.6]</strong></p></td></tr><tr><td><p dir="ltr"><strong>Key Endpoints</strong></p></td><td colspan="2">&nbsp;</td></tr><tr><td><p dir="ltr"><strong>IRC-assessed PFS (PFS-IRC)&nbsp;</strong></p></td><td colspan="2">&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Number (%) of patients with event&nbsp;</strong></p></td><td><p dir="ltr"><strong>125 (20.8%)</strong></p></td><td><p dir="ltr"><strong>93 (15.5%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>HR [95% CI]</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.71 [0.54, 0.93]</strong></p></td></tr><tr><td><p dir="ltr"><strong>p-value (Log-Rank test, stratified*)</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.0138</strong></p></td></tr><tr><td><p dir="ltr"><strong>Time to next anti-lymphoma therapy#&nbsp;</strong></p></td><td colspan="2">&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Number (%) of patients with event&nbsp;</strong></p></td><td><p dir="ltr"><strong>111 (18.5%)</strong></p></td><td><p dir="ltr"><strong>80 (13.3%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>HR [95% CI]</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.68 [0.51, 0.91]</strong></p></td></tr><tr><td><p dir="ltr"><strong>p-value (Log-Rank test, stratified*)</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.0094</strong></p></td></tr><tr><td><p dir="ltr"><strong>Overall Survival#</strong></p></td><td colspan="2">&nbsp;</td></tr><tr><td><p dir="ltr"><strong>No. (%) of patients with event</strong></p></td><td><p dir="ltr"><strong>46 (7.7%)</strong></p></td><td><p dir="ltr"><strong>35 (5.8%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>HR [95% CI]</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.75 [0.49, 1.17] &para;</strong></p></td></tr><tr><td><p dir="ltr"><strong>p-value (Log-Rank test, stratified*)</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.21&para;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Overall Response Rate** at End of Induction&Dagger; (INV-assessed, CT) #</strong></p></td><td colspan="2"><br />&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Responders (%) (CR, PR)</strong></p></td><td><p dir="ltr"><strong>522 (86.9%)</strong></p></td><td><p dir="ltr"><strong>532 (88.5%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Difference in response rate (%) [95% CI]</strong></p></td><td colspan="2"><p dir="ltr"><strong>1.7% [-2.1%, 5.5%]</strong></p></td></tr><tr><td><p dir="ltr"><strong>p-value (Cochran-Mantel-Haenszel test)</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.33</strong></p></td></tr><tr><td><p dir="ltr"><strong>Complete Response (CR)</strong></p></td><td><p dir="ltr"><strong>143 (23.8%)</strong></p></td><td><p dir="ltr"><strong>117 (19.5%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Partial Response (PR)</strong></p></td><td><p dir="ltr"><strong>379 (63.1%)</strong></p></td><td><p dir="ltr"><strong>415 (69.1%)</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>IRC: Independent Review Committee; PFS: progression-free survival; HR: Hazard Ratio; CI: Confidence Interval</strong></p><p dir="ltr"><strong>* Stratification factors were chemotherapy regimen, FLIPI risk group for follicular lymphoma, geographic region&nbsp;</strong></p><p dir="ltr"><strong>&sect; Significance level at this efficacy interim analysis: 0.012</strong></p><p dir="ltr"><strong>&para; Data Not Yet Mature. Median&nbsp; was not reached at time of analysis</strong></p><p dir="ltr"><strong># not adjusted for multiplicity</strong></p><p dir="ltr"><strong>**Assessed as per modified Cheson 2007 criteria</strong></p><p dir="ltr"><strong>&Dagger; End of Induction = end of induction phase, does not include monotherapy maintenance</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>Figure 4 Kaplan-Meier curve of INV-assessed progression-free survival in patients with previously untreated FL (Study BO21223/GALLIUM)</strong></p><p dir="ltr"><strong><img width="474" height="294" src="https://lh3.googleusercontent.com/1J3b2c-tZYDVgWU9da2WISp9xOXn6TwFf4H1dHdtb-dE5adgW8hT3yx7w79ANCpzuOZMabgC4n62hImRZx-bkGBWj8zx0olqO4Rw-Yt0s3Dn-TI3IErSGoGZbRZpCDnNl4GX--A" />&nbsp;</strong></p><p dir="ltr"><strong>R-Chemo: Rituximab plus chemotherapy, G-Chemo: Gazyva plus chemotherapy, HR: hazard ratio, CI: confidence interval</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Results of subgroup analyses</strong></p><p dir="ltr"><strong>Results of subgroup analyses (not adjusted for multiplicity) were, in general, consistent with the results seen in the FL population, supporting the robustness of the overall result. The subgroups evaluated included IPI, FLIPI, Bulky Disease, B Symptoms at baseline, Ann Arbor Stage and ECOG at baseline. In patients with FLIPI score 0-1 (low risk), no difference between Gazyva plus chemotherapy and rituximab plus chemotherapy was observed (INV-assessed PFS HR 1.17 (95%CI 0.63;2.19, 40 PFS events).&nbsp; This subgroup&nbsp; comprised 21% (253/1202) of the FL ITT&nbsp; population and&nbsp; experienced 16.3% (40/245) of the PFS events. In addition, exploratory subgroup analyses of PFS across chemotherapy regimens (bendamustine, CHOP and CVP) were consistent with the results seen in the Gazyva plus chemotherapy population. The observed HRs by chemotherapy subgroup were as follows; CHOP (n&nbsp;=&nbsp;398): HR&nbsp;0.77 (95% CI: 0.50, 1.20), CVP (n&nbsp;=&nbsp;118): HR 0.63 (95% CI: 0.32, 1.21), and bendamustine (n&nbsp;=&nbsp;686): HR 0.61 (95% CI: 0.43, 0.86).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patient Reported Outcomes&nbsp;</strong></p><p dir="ltr"><strong>Based on the FACT-Lym questionnaire collected during treatment and follow-up phases, patients in both treatment arms experienced clinically meaningful improvements in lymphoma-related symptoms as defined by a &ge;&nbsp;3 point increase from baseline in the Lymphoma subscale, a &ge;&nbsp;6 point increase from baseline in the FACT Lym TOI and a&nbsp;&ge;&nbsp;7 point increase from baseline in the FACT Lym Total score. EQ-5D utility scores were similar at baseline, during treatment and follow-up. No meaningful differences were seen between the arms in HRQOL or health status measures.</strong></p><p dir="ltr"><strong>Due to the open label design the patient reported outcomes should be interpreted with caution.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen (study GAO4753g/GADOLIN).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In a phase III, open label, multicentre, randomised clinical study (GAO4753g/GADOLIN), 396&nbsp;patients with iNHL who had no response during treatment or who progressed within 6 months following the last dose of rituximab or a rituximab-containing regimen (including rituximab monotherapy as part of induction or maintenance treatment) were evaluated. Patients were randomised 1:1 to receive either bendamustine (B) alone (n = 202) or Gazyva in combination with bendamustine (G+B) (n = 194) for 6 cycles, each of 28 days duration. Patients in the G+B arm who did not have disease progression (i.e. patients with a complete response (CR), partial response (PR) or stable disease (SD)) at the end of induction continued receiving Gazyva maintenance once every two months for two years or until disease progression (whichever occurred first). Patients were stratified according to region, iNHL subtype (follicular versus non-follicular), rituximab-refractory type (whether refractory to prior rituximab monotherapy or rituximab in combination with chemotherapy) and the number of prior therapies (&le; 2 versus &gt; 2).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The demographic data and baseline characteristics were well balanced between the treatment arms (median age 63 years, the majority were Caucasian [88%] and male [58%]). The majority of patients had follicular lymphoma (81%). The median time from initial diagnosis was 3 years and the median number of prior therapies was 2 (range 1 to 10); 44% of patients had received 1 prior therapy and 34% of patients had received 2 prior therapies.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Gazyva was given by intravenous infusion as a dose of 1,000 mg on Days 1, 8 and 15 of Cycle 1, on Day 1 of Cycles 2-6, and in patients who did not have disease progression, once every two months for two years or until disease progression (whichever occurs first). Bendamustine was given intravenously on Days 1 and 2 for all treatment cycles (Cycles 1-6) at 90 mg/m2/day when given in combination with Gazyva or 120 mg/m2/day when given alone. In patients treated with G+ B, 79.4% received all six treatment cycles compared to 66.7% of patients in the B arm.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The primary analysis based on independent Review Committee (IRC) assessment demonstrated a statistically significant - 45% reduction in the risk of disease progression or death, in patients with iNHL receiving G+B followed by Gazyva maintenance, compared with patients receiving bendamustine alone. The reduction in the risk of disease progression or death seen in the iNHL population is driven by the subset of patients with FL.</strong></p><p dir="ltr"><strong>The majority of the patients in study GAO4753g had FL (81.1%). Efficacy results in the FL population are shown in Table 9. 11.6% of the patients had marginal zone lymphoma (MZL) and 7.1% had small lymphocytic lymphoma (SLL).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table&nbsp;9 Summary of efficacy in patients with FL# from GAO4753g/GADOLIN study</strong></p><table><tbody><tr><td>&nbsp;</td><td colspan="2">&nbsp;</td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Bendamustine</strong></p><p dir="ltr"><strong>N=166</strong></p></td><td><p dir="ltr"><strong>Gazyva + Bendamustine followed by Gazyva maintenance</strong></p><p dir="ltr"><strong>N=155</strong></p></td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Median observation time: 20 months</strong></p></td><td><p dir="ltr"><strong>Median observation time: 22 months</strong></p></td></tr><tr><td><p dir="ltr"><strong>Primary Endpoint in FL population</strong></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>IRC-assessed PFS (PFS-IRC)</strong></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Number (%) of patients with event&nbsp;</strong></p></td><td><p dir="ltr"><strong>90 (54.2%)</strong></p></td><td><p dir="ltr"><strong>54 (34.8%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median time to event (months, 95% CI)</strong></p></td><td><p dir="ltr"><strong>13.8 (11.4, 16.2)</strong></p></td><td><p dir="ltr"><strong>NR (22.5,-)</strong></p></td></tr><tr><td><p dir="ltr"><strong>HR (95% CI)</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.48 (0.34, 0.68)</strong></p></td></tr><tr><td><p dir="ltr"><strong>p-value (Log-Rank test, stratified*)</strong></p></td><td colspan="2"><p dir="ltr"><strong>&lt; 0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>Secondary Endpoints</strong></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Investigator-assessed PFS (PFS-INV)</strong></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Number (%) of patients with event&nbsp;</strong></p></td><td><p dir="ltr"><strong>102 (61.4%)</strong></p></td><td><p dir="ltr"><strong>62 (40.0%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median time to event (months, 95% CI)</strong></p></td><td><p dir="ltr"><strong>13.7 (11.0, 15.5)</strong></p></td><td><p dir="ltr"><strong>29.2 (17.5,-)</strong></p></td></tr><tr><td><p dir="ltr"><strong>HR (95% CI)</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.48 (0.35, 0.67)</strong></p></td></tr><tr><td><p dir="ltr"><strong>p-value (Log-Rank test, stratified*)</strong></p></td><td colspan="2"><p dir="ltr"><strong>&lt; 0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>Best Overall Response (BOR) (IRC-assessed)&sect;</strong></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>No. of patients included in the analysis</strong></p></td><td><p dir="ltr"><strong>161</strong></p></td><td><p dir="ltr"><strong>153</strong></p></td></tr><tr><td><p dir="ltr"><strong>Responders (%) (CR/PR)</strong></p></td><td><p dir="ltr"><strong>124 (77.0%)</strong></p></td><td><p dir="ltr"><strong>122 (79.7%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Difference in response rate (95% CI)</strong></p></td><td colspan="2"><p dir="ltr"><strong>2.72 (-6.74, 12.18)</strong></p></td></tr><tr><td><p dir="ltr"><strong>p-value (Cochran-Mantel-Haenszel test)</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.6142</strong></p></td></tr><tr><td><p dir="ltr"><strong>Complete Responders (%)</strong></p></td><td><p dir="ltr"><strong>31 (19.3%)</strong></p></td><td><p dir="ltr"><strong>24 (15.7%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Partial Responders (%)</strong></p></td><td><p dir="ltr"><strong>93 (57.8%)</strong></p></td><td><p dir="ltr"><strong>98 (64.1%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Stable Disease (%)</strong></p></td><td><p dir="ltr"><strong>18 (11.2%)</strong></p></td><td><p dir="ltr"><strong>13 (8.5%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Duration of response (DOR) (IRC-assessed)</strong></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>No of patients included in the analysis</strong></p></td><td><p dir="ltr"><strong>127</strong></p></td><td><p dir="ltr"><strong>122</strong></p></td></tr><tr><td><p dir="ltr"><strong>No. (%) of patients with event</strong></p></td><td><p dir="ltr"><strong>74 (58.3%)</strong></p></td><td><p dir="ltr"><strong>36 (29.5%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median duration (months) of DOR (95% CI)</strong></p></td><td><p dir="ltr"><strong>11.9 (8.8, 13.6)</strong></p></td><td><p dir="ltr"><strong>NR (25.4,-)</strong></p></td></tr><tr><td><p dir="ltr"><strong>HR (95% CI)</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.36 (0.24, 0.54)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Overall Survival (not yet mature)</strong></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>No. (%) of patients with event</strong></p></td><td><p dir="ltr"><strong>36 (21.7%)</strong></p></td><td><p dir="ltr"><strong>25 (16.1%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median time to event (months)</strong></p></td><td><p dir="ltr"><strong>NR</strong></p></td><td><p dir="ltr"><strong>NR</strong></p></td></tr><tr><td><p dir="ltr"><strong>HR (95% CI)</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.71 (0.43, 1.19)</strong></p></td></tr><tr><td><p dir="ltr"><strong>p-value (Log-Rank test, stratified*)</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.1976</strong></p></td></tr></tbody></table><p dir="ltr"><strong>IRC: Independent Review Committee; PFS: progression-free survival; HR: Hazard Ratio; CI: Confidence Intervals,&nbsp;</strong></p><p dir="ltr"><strong>NR = Not Reached</strong></p><p dir="ltr"><strong># Patients with FL who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen</strong></p><p dir="ltr"><strong>*Stratification factors for analysis were refractory type (rituximab monotherapy vs. rituximab + chemotherapy) and prior therapies (&le; 2 vs &gt; 2). Follicular versus non-follicular was also a stratification factor for the study but is not applicable in the subgroup analysis of patients with FL.&nbsp;</strong></p><p dir="ltr"><strong>&sect; Best response within 12 months of start of treatment</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the non-FL population the HR for IRC-assessed PFS was 0.94 [95% CI: 0.49, 1.90].&nbsp;</strong></p><p dir="ltr"><strong>No definitive conclusions could be drawn on efficacy in the MZL and SLL sub-populations.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Figure 5 Kaplan-Meier curve of IRC-assessed PFS in patients with FL # (Study GAO4753g/GADOLIN)</strong></p><p dir="ltr"><strong><img width="307" height="267" src="https://lh5.googleusercontent.com/AdlPuA-ndbJjOE-mwIm2vn6OMxdwVhf4cH_BM8zaIPSbaojYeiw1Bw7fxcNXoVX5dYo-wdIbVt-kRCRP6i5HNCr8PQqu5o-J3bBNqAdrvK6S1IrNIUDGtBg9WxhL7Kxd4PX_SaI" /></strong></p><p dir="ltr"><strong># Patients with FL who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Figure 6 Kaplan-Meier curve of OS in patients with FL # (Study GAO4753g/GADOLIN)</strong></p><p>&nbsp;</p><p dir="ltr"><strong><img alt="Updated OS " width="320" height="280" src="https://lh3.googleusercontent.com/uaIc7ZMcd7fRDQiageE2_1JLdPKlX9U7ZTRFwU8YhbcTxHGzZHoiO0u74kb8vW6QfhziXCEaaYIRbUrstxFD_onLZ1yfKT99LxtTGTukg_QJQd2DOpOv9OnZ22KrvLmFAiFYP0w" /></strong></p><p dir="ltr"><strong># Patients with FL who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen</strong></p><p>&nbsp;</p><p dir="ltr"><strong>A post hoc analysis was performed 8 months after the primary analysis data cut. With a median observation time of 24.1 months for FL patients, 48 patients (28.1%) in the B arm and 30 patients (18.3%) in the G+B arm had died. The observed improvement in OS seen with G+B was supported by a stratified HR for OS of 0.62 (95% CI: 0.39, 0.98) in this post hoc analysis. The median OS was not yet reached for either arm. The PFS results in the post hoc analysis are consistent with the primary analysis and its significance is unchanged and the safety profile is consistent with the primary analysis.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Results of subgroup analyses</strong></p><p dir="ltr"><strong>Results of subgroup analyses were in general consistent with the results seen in the FL population, supporting the robustness of the overall result.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Figure 7 IRC-assessed PFS by patient subgroup in FL *# (Study GAO4753g/GADOLIN)</strong></p><p><br /><strong><img width="605" height="417" src="https://docs.google.com/drawings/u/0/d/s7K4CoG97yz_GS62H8gvzzQ/image?w=605&amp;h=417&amp;rev=1&amp;ac=1&amp;parent=1Hhej4wwBJSJFe0QYXUQ69gMTg_-E1mG6" /><img width="604" height="416" src="https://lh5.googleusercontent.com/ke69V9C0YlZtkwKTQu8SApk4fpXmb3pggWZI5d9NYD2H0n93lqYixS0c4VPtsQEYlBU5LBvSRIIPvEcBxru2j0Vkz-CVh8Rt7uCv32_bjfNWoGYBT6It6gTKI4plfip1PjG-H9k" /></strong></p><p dir="ltr"><strong>*pre-specified analyses performed on the intent to treat (ITT) population were repeated on the FL population; analysis of double refractory (i.e. unresponsive to or disease progression during or within 6 months of the last dose of an alkylating agent-based regimen) status was exploratory.&nbsp;</strong></p><p dir="ltr"><strong># Patients with FL who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patient-reported Outcomes</strong></p><p dir="ltr"><strong>Due to the open label design the patient reported outcomes should be interpreted with caution. Based on the FACT-Lym questionnaire and EQ-5D index scale collected during the treatment and during follow-up periods, health-related quality of life was generally maintained in the pivotal study with no meaningful difference between the arms. However, in patients with FL the addition of Gazyva to bendamustine delayed the time to worsening of health-related quality of life as measured by the FACT-Lym TOI score by 2.2 months (median 5.6 versus 7.8 months for B and G+B respectively HR&nbsp;=&nbsp;0.83; 95% CI: 0.60, 1.13).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Immunogenicity</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Immunogenicity assay results are highly dependent on several factors including assay sensitivity and specificity, assay methodology, assay robustness to quantities of Gazyva/antibody in the circulation, sample handling, timing of sample collection, concomitant medicines and underlying disease. For these reasons, comparison of incidence of antibodies to Gazyva with the incidence of antibodies to other products may be misleading.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients in the CLL pivotal study BO21004/CLL11 were tested at multiple time-points for antitherapeutic antibodies (ATA) to Gazyva. In patients treated with Gazyva 8&nbsp;out of&nbsp;140 patients in the randomised phase and 2&nbsp;out of&nbsp;6 in the run in phase tested positive for ATA at 12&nbsp;months of follow up. Of these patients, none experienced anaphylactic or hypersensitivity reactions that were considered related to ATA, nor was clinical response affected.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>No post-baseline HAHA (Human Anti-Human Antibody) were observed in patients with iNHL treated in study GAO4753g/GADOLIN. In study BO21223/GALLIUM, 1/565 patient (0.2% of patients with a post-baseline assessment) developed HAHA at induction completion. While the clinical significance of HAHA is not known, a potential correlation between HAHA and clinical course cannot be ruled out.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The European Medicines Agency has waived the obligation to submit the results of studies with Gazyva in all subsets of the paediatric population in CLLand FL (see section 4.2 for information on paediatric use).</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>A population pharmacokinetic (PK) model was developed to analyse the PK data in 469 iNHL, 342&nbsp;CLL and 130 diffuse large B-cell lymphoma (DLBCL) patients from Phase I, Phase II and Phase III studies who received obinutuzumab alone or in combination with chemotherapy.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Absorption</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Obinutuzumab is administered intravenously, therefore absorption is not applicable. There have been no studies performed with other routes of administration. From the population PK model, after the Cycle&nbsp;6 Day&nbsp;1 infusion in CLL patients, the estimated median Cmax value was 465.7 &mu;g/mL and AUC(&tau;) value was 8961&nbsp;&mu;g&bull;d/mL and in iNHL patients the estimated median Cmax value was 539.3&nbsp;&mu;g/mL and AUC(&tau;) value was 10956 &mu;g&bull;day/mL.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Distribution</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Following intravenous administration, the volume of distribution of the central compartment (2.98 L in patients with CLL and 2.97 in patients with iNHL), approximates serum volume, which indicates distribution is largely restricted to plasma and interstitial fluid.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Biotransformation</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The metabolism of obinutuzumab has not been directly studied. Antibodies are mostly cleared by catabolism.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elimination</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The clearance of obinutuzumab was approximately 0.11 L/day in CLL patients and 0.08 L/day in iNHL patients with a median elimination t&frac12; of 26.4&nbsp;days in CLL patients and 36.8 days in iNHL patients. Obinutuzumab elimination comprises two parallel pathways which describe clearance, a linear clearance pathway and a non-linear clearance pathway which changes as a function of time. During the initial treatment, the non-linear time-varying clearance pathway is dominant and is consequently the major clearance pathway. As treatment continues, the impact of this pathway diminishes and the linear clearance pathway predominates. This is indicative of target mediated drug disposition (TMDD), where the initial abundance of CD20 cells causes a rapid removal of obinutuzumab from the circulation. However, once the majority of CD20 cells are bound with obinutuzumab, the impact of TMDD on PK is minimised.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pharmacokinetic/pharmacodynamic relationship(s)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the population pharmacokinetic analysis, gender was found to be a covariate which explains some of the inter-patient variability, with a 22% greater steady state clearance (CLss) and a 19% greater volume of distribution (V) in males. However, results from the population analysis have shown that the differences in exposure are not significant (with an estimated median AUC and Cmax in CLL patients of 11282&nbsp;&micro;g&bull;d/mL and 578.9&nbsp;&micro;g/mL in females and 8451&nbsp;&micro;g&bull;d/mL&nbsp;and 432.5&nbsp;&micro;g/mL in males, respectively at Cycle&nbsp;6 and AUC and Cmax in iNHL of 13172 &micro;g&bull;d/mL and 635.7 &micro;g/mL in females and 9769 &micro;g&bull;d/mL and 481.3 &micro;g/mL in males, respectively), indicating that there is no need to dose adjust based on gender.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elderly</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The population pharmacokinetic analysis of obinutuzumab showed that age did not affect the pharmacokinetics of obinutuzumab. No significant difference was observed in the pharmacokinetics of obinutuzumab among patients &lt;&nbsp;65&nbsp;years (n=375), patients between 6575 years (n=265) and patients &gt;&nbsp;75&nbsp;years (n=171).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population</strong></p><p>&nbsp;</p><p dir="ltr"><strong>No studies have been conducted to investigate the pharmacokinetics of obinutuzumab in paediatric patients.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Renal impairment</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The population pharmacokinetic analysis of obinutuzumab showed that creatinine clearance does not affect pharmacokinetics of obinutuzumab. Pharmacokinetics of obinutuzumab in patients with mild creatinine clearance (CrCl 5089&nbsp;mL/min, n=464) or moderate (CrCl 30&nbsp;to&nbsp;49&nbsp;mL/min, n=106) renal impairment were similar to those in patients with normal renal function (CrCl &ge;&nbsp;90&nbsp;mL/min, n=383). Pharmacokinetic data in patients with severe renal impairment (CrCl 1529&nbsp;mL/min) is limited (n=8), therefore no dose recommendations can be made.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hepatic impairment</strong></p><p>&nbsp;</p><p dir="ltr"><strong>No formal pharmacokinetic study has been conducted in patients with hepatic impairment.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>No studies have been performed to establish the carcinogenic potential of obinutuzumab.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>No specific studies in animals have been performed to evaluate the effect of obinutuzumab on fertility. In repeat-dose toxicity studies in cynomolgus monkeys obinutuzumab had no adverse effects on male and female reproductive organs.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>An enhanced pre and postnatal development (ePPND) toxicity study in pregnant cynomolgus monkeys showed no evidence of teratogenic effects. However, weekly obinutuzumab dosing from post-coitum day 20 to delivery resulted in complete depletion of B-cells in infant monkeys at weekly intravenous obinutuzumab doses of 25 and 50&nbsp;mg/kg (25 times the clinical exposure based on Cmax and AUC). Offspring exposure on day&nbsp;28 post-partum suggests that obinutuzumab can cross the blood-placenta barrier. Concentrations in infant serum on day&nbsp;28 post-partum were in the range of concentrations in maternal serum, whereas concentrations in milk on the same day were very low (less than 0.5% of the corresponding maternal serum levels) suggesting that exposure of infants must have occurred in utero. The B-cell counts returned to normal levels, and immunologic function was restored within 6 months post-partum.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In a 26week cynomolgus monkey study, hypersensitivity reactions were noted and attributed to the foreign recognition of the humanised antibody in cynomolgus monkeys (0.76 times the clinical exposure based on Cmax and AUC at steady state after weekly administration of 5, 25, and 50&nbsp;mg/kg). Findings included acute anaphylactic or anaphylactoid reactions and an increased prevalence of systemic inflammation and infiltrates consistent with immunecomplex mediated hypersensitivity reactions, such as arteritis/periarteritis, glomerulonephritis, and serosal/adventitial inflammation. These reactions led to unscheduled termination of 6/36 animals treated with obinutuzumab during dosing and recovery phases; these changes were partially reversible. No renal toxicity with a causal relationship to obinutuzumab has been observed in humans.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>L-histidine</strong></p><p dir="ltr"><strong>L-histidine hydrochloride monohydrate</strong></p><p dir="ltr"><strong>Trehalose dihydrate</strong></p><p dir="ltr"><strong>Poloxamer 188</strong></p><p dir="ltr"><strong>Water for injections</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial
3 years.

After dilution
After dilution, chemical and physical stability have been demonstrated in sodium chloride 9 mg/mL (0.9%) solution for injection at concentrations of 0.4 mg/mL to 20 mg/mL for 24 hours at 2°C to 8°C followed by 48 hours (including infusion time) at ≤ 30°C.    

From a microbiological point of view, the prepared infusion solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C8°C, unless dilution has taken place in controlled and validated aseptic conditions.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Store in a refrigerator (2&deg;C8&deg;C).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Do not freeze.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Keep the vial in the outer carton in order to protect from light.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For storage conditions after dilution of the medicinal product, see section 6.3.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>40&nbsp;mL concentrate in a 50&nbsp;mL vial&nbsp; (clear Type I glass) with stopper (butyl rubber). Pack size of&nbsp;1 vial.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Instructions for dilution</strong></p><p dir="ltr"><strong>Gazyva should be prepared by a healthcare professional using aseptic technique. Do not shake the vial.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For CLL cycles 2 &ndash; 6 and all FL cycles</strong></p><p dir="ltr"><strong>Withdraw 40&nbsp;mL of concentrate from the vial and dilute in polyvinyl chloride (PVC) or non-PVC polyolefin infusion bags containing sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection.&nbsp;</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>CLL only &ndash; Cycle 1&nbsp;</strong></p><p dir="ltr"><strong>To ensure differentiation of the two infusion bags for the initial 1,000&nbsp;mg dose, it is recommended to utilise bags of different sizes to distinguish between the 100&nbsp;mg dose for Cycle&nbsp;1 Day&nbsp;1 and the 900&nbsp;mg dose for Cycle&nbsp;1 Day&nbsp;1 (continued) or Day&nbsp;2. To prepare the 2 infusion bags, withdraw 40&nbsp;mL of concentrate from the vial and dilute 4&nbsp;mL into a 100&nbsp;mL PVC or non-PVC polyolefin infusion bag and the remaining 36&nbsp;mL in a 250&nbsp;mL PVC or non-PVC polyolefin infusion bag containing sodium chloride 9&nbsp;mg/ml (0.9%) solution for injection. Clearly label each infusion bag. For storage conditions of the infusion bags see section 6.3.</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Dose of Gazyva to be administered</strong></p></td><td><p dir="ltr"><strong>Required amount of Gazyva concentrate</strong></p></td><td><p dir="ltr"><strong>Size of PVC or non-PVC polyolefin infusion bag</strong></p></td></tr><tr><td><p dir="ltr"><strong>100&nbsp;mg</strong></p></td><td><p dir="ltr"><strong>4&nbsp;mL</strong></p></td><td><p dir="ltr"><strong>100&nbsp;mL</strong></p></td></tr><tr><td><p dir="ltr"><strong>900&nbsp;mg</strong></p></td><td><p dir="ltr"><strong>36&nbsp;mL</strong></p></td><td><p dir="ltr"><strong>250&nbsp;mL</strong></p></td></tr><tr><td><p dir="ltr"><strong>1000&nbsp;mg</strong></p></td><td><p dir="ltr"><strong>40&nbsp;mL</strong></p></td><td><p dir="ltr"><strong>250&nbsp;mL</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>Do not use other diluents such as glucose (5%) solution (see section 6.2).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The bag should be gently inverted to mix the solution in order to avoid excessive foaming. The diluted solution should not be shaken or frozen.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Parenteral medicinal products should be inspected visually for particulates and discolouration prior to administration.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>No incompatibilities have been observed between Gazyva, in concentration ranges from 0.4&nbsp;mg/mL to 20.0&nbsp;mg/mL after dilution of Gazyva with sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection, and:</strong></p><p dir="ltr"><strong>- PVC, polyethylene (PE), polypropylene or polyolefin bags</strong></p><p dir="ltr"><strong>- PVC, polyurethane (PUR) or PE infusion sets</strong></p><p dir="ltr"><strong>- optional inline filters with product contact surfaces of polyethersulfone (PES), a 3way stopcock infusion aid made from polycarbonate (PC), and catheters made from polyetherurethane (PEU).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Disposal</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                F. Hoffmann-La Roche Ltd,
Grenzacherstrasse 124, 
CH-4070 Basel, 
Switzerland.
8.	MARKETING AUTHORISATION NUMBER(S) 

282-24-16


9.	DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorization: 31 August 2016

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                26 October 2017

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>